Injector system

Abstract
An injector including at least one fluid reservoir having a needle, a surface attached to skin and coupled to the fluid reservoir by at least a first joint and a second joint at least a portion of one of the joints being slidable or having interlocking arms. At least a portion of a path of translation of a slidable portion of the first joint and a portion of a path of translation of the second joint are angled in respect to each another.
Description
FIELD AND BACKGROUND OF THE INVENTION

The present invention, in some embodiments thereof, relates to a self-injector and, more particularly, but not exclusively, to a patch self-injector.


A subcutaneous (SC) injection is a method of administering medication under the skin, commonly into fatty tissue between the skin and the muscle. The current trend toward subcutaneous injection for biologicals using auto-injectors such as, for example, reusable and disposable pens, auto-injectors, and patch injectors that adhere to the surface of the skin gives users the freedom to self-inject at home.


In many cases, reformulated drugs can be more concentrated, at times more viscous and the desired injection volume greater than 1 mL. For high viscosity products, delivery in under 10 seconds can lead to painful injections, which may result in users failing to follow their treatment regimen. It may be difficult at times for a user to keep a Pen or any other upright injector stationary and at a correct angle of injection during injections for periods of over 10 seconds or several minutes. Patch auto or self-injectors for self-administered SC injections are therefore becoming more common.


Additional background art includes U.S. Pat. Nos. 6,843,782 and 5,858,001.


SUMMARY OF THE INVENTION

According to an aspect of some embodiments of the present invention there is provided an injector including one or more fluid reservoirs having a needle, a surface attached to skin and coupled to the fluid reservoir by one or more first joint and a second joint one or more portions of one of the joints being slidable.


According to some embodiments of the invention one or more portion of a path of translation of the slidable portion of the first joint and a portion of a path of translation of the second joint are angled in respect to each another and one or more portion of the path of translation of the portion of the second joint restricts the one or more portion of the path of translation of the portion of the first joint.


According to some embodiments of the invention, one or more portion of the path of translation of the second joint is curved. According to some embodiments of the invention one or more portion of the path of translation of the second joint is sinusoidal.


According to some embodiments of the invention, one or more portion of the path of translation of the second joint is serpentine.


According to some embodiments of the invention, one or more of the joints has at least two degrees of freedom in respect to the surface, one or more being a rotational degree of freedom both degrees of freedom being on a same plane. When the fluid reservoir is rotated in respect to the surface, one or more portion of a path of travel of one or more portion of the needle defined by at least the two degrees of freedom crosses a surface of the skin along a straight line. According to some embodiments of the invention, the portion is the proximal edge of a bevel of the needle. According to some embodiments of the invention, a tilt angle of the needle is generally parallel to the straight path. According to some embodiments of the invention, the needle forms an entry hole in skin with a diameter (Φ) being twice the diameter (Φ′) of the needle.


According to some embodiments of the invention, when the fluid reservoir is rotated in respect to the surface, one or more portion of a path of travel of one or more portion of the needle defined by at least the two paths of translation crosses a surface of the skin along a straight line. According to some embodiments of the invention, one or more of the paths translation is parallel to the skin and the needle travels along a path one or more portion of which is defined by a combination of the rotational degree of freedom and the translational degree of freedom.


According to some embodiments of the invention, the needle travels along a path one or more portion of which is defined by one or more of the rotational degree of freedom and the translational degree of freedom. According to some embodiments of the invention, the portion is a tip of the needle. According to some embodiments, the portion is the upper end of a bevel of the needle.


According to some embodiments of the invention, at least the two degrees of freedom define a path of travel at which one or more portion of the needle crosses the surface of the skin angled at less than 3 degrees in respect to the straight line. According to some embodiments of the invention, the portion is a tip that includes a beveled opening facing forward (away from the body of the fluid reservoir) and one or more portion of the needle is tangential to a curve defined by the rotational degree of freedom. According to some embodiments of the invention, one or more portion of the needle is normal to a radius of a curve defined by the rotational degree of freedom.


According to some embodiments of the invention, one or more of the joints includes one or more pin-in-slot hinge. According to some embodiments of the invention, one or more slot is oriented parallel to the surface of the skin. According to some embodiments of the invention, one or more of the first and second joints is located between the back end (non-needle end) and front end (needle end) of the injector.


According to some embodiments of the invention, the fluid reservoir further includes one or more angled head and plunger coupled to a tip of the head and wherein one or more of the joints includes one or more slotted cylinder coupled to the surface and sized and fitted to slidingly accommodate the angled head and the plunger.


According to some embodiments of the invention, one or more portion of the needle is resilient. According to some embodiments of the invention, one or more portion of the needle is curved. According to some embodiments of the invention, one or more joint includes one or more groove and one or more protrusion slidingly accommodated within the groove. According to some embodiments of the invention, one or more joint includes an elastic member.


According to an aspect of some embodiments of the present invention there is provided an injector, including one or more fluid reservoir having a needle, a surface attached to skin and coupled to the fluid reservoir by one or more first joint and a second joint one or more joint including at least two interlocking arms. According to some embodiments of the invention, one or more of the interlocking arms is pivotly coupled to the surface. According to some embodiments of the invention, the interlocking arms are pivotly coupled to each other.


According to an aspect of some embodiments of the present invention there is provided a method of injection, including rotating a needle of a fluid reservoir in respect to a surface of skin, concurrently moving the needle along a translational degree of freedom and inserting one or more portion of the needle across the surface of skin along a straight line. According to some embodiments of the invention, inserting one or more portion of the needle across the surface of skin angled at less than 3 degrees from the straight line. According to some embodiments of the invention, the translational degree of freedom is axial in respect to the skin. According to some embodiments of the invention, the movement in the translational degree of freedom is a in a back and forth direction. According to some embodiments of the invention, the concurrently rotating and moving the needle includes adjusting a path of travel and/or angle of tilt of a needle entering the skin. According to some embodiments of the invention, further including minimizing backpressure on a bevel of the needle to a backpressure of between 80-85% of the backpressure before adjustment.


According to some embodiments of the invention, further including forming an entry hole in skin with a diameter (Φ) being twice the diameter (Φ′) of the needle.


Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.





BRIEF DESCRIPTION OF THE SEVERAL VIEW OF THE DRAWINGS

Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.


In the drawings:



FIGS. 1A and 1B are cross section view simplified illustrations of a self-injector as known in the art;



FIG. 2 is a simplified diagram of formation of a curvilinear path by a tangential point connected to a rotation point via a fixed-length radius;



FIGS. 3A, 3B and 3C are simplified diagrams of optional joints that convert a curvilinear path of travel of a tangential point connected to a point of rotation via a radius to a substantially straight path of motion;



FIGS. 4 A, 4B and 4C are side-view simplified illustrations of operative stages of an exemplary embodiment of a self-injector;



FIGS. 5A, 5B, 5C, 5D and 5E are side view, simplified illustrations of a self-injector needle and the effect of the joint on needle angle at penetration of the needle into skin;



FIGS. 5F and 5G are graphs showing the effect of injector joint adjustment, on back pressure on the bevel of a needle entering the skin;



FIGS. 6A, 6B, 6C and 6D are side-view and cross-section view simplified illustrations of operative stages of an exemplary embodiment of a self-injector;



FIGS. 7A, 7B, 7C and 7D are side-view and cross-section view simplified illustrations of operative stages of an exemplary embodiment of a self-injector;



FIGS. 8 A, 8B and 8C are side-view and top view simplified illustrations of exemplary embodiments of a self-injector; and



FIGS. 9 A and 9B are side-view simplified illustrations of an exemplary embodiment of a self-injector in accordance with the invention.





DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION

The present invention, in some embodiments thereof, relates to self-injectors and, more particularly, but not exclusively, to a patch self-injector.


An aspect of some embodiments of the invention relates to a self-injector having at least two joints connecting at least a portion of a surface attached to skin and a fluid reservoir, at least a portion of one of the joints being slidable in respect to other portion of joint. In some embodiments, at least one joint comprises a sliding joint. In some embodiments, the path of translation of the second joint restricts the path of translation of the portion of the first joint. In some embodiments, the restriction depends on an angle between the paths of translation. In some embodiments the angle is a sharp angle. In some embodiments the angle is less than 90 degrees. In some embodiments, paths of translation of the two joints are on the same plane.


In some embodiments, the fluid reservoir is a syringe. In some embodiments, the fluid reservoir is a cartridge. In some embodiments, the fluid reservoir is a vial.


In some embodiments, the joint comprises at least one slot. In some embodiments, the joint comprises at least one rail. In some embodiments, the joint comprises at least one groove. In some embodiments, the joint comprises at least one sleeve. In some embodiments, the sleeve is positioned about the needle. In some embodiments, the sleeve comprises at least one slot. In some embodiments, the fluid reservoir and frame are slidable in respect to each other. In some embodiments, at least one joint comprises at least two interlocking arms.


In some embodiments, at least one joint is disposed at the back end (non-needle end) of the injector. In some embodiments, at least one joint is disposed at the front end (needle end) of the injector. In some embodiments at least one joint is disposed between the back end (non-needle end) and front end (needle end) of the injector. In some embodiments, the angle of penetration of the injection needle changes while maintaining the point of entry into the skin. In some embodiments, the injection needle moves concurrently along at least two planes changing its angle of penetration in respect to the path of travel while maintaining the point of entry into the skin.


In some embodiments, at least one of the joints comprises a planar joint. In some embodiments, at least one of the joints comprises a non-planar joint. In some embodiments, the joint injector comprises both a planar joint and a non-planar joint. In some embodiments, at least portions of the joint planar joint and non-planar joint are on the same plane, the plane being normal to the axis of rotation. In some embodiments, the planar joint and non-planar joint are not on the same plane, the plane being normal to the axis of rotation. In some embodiments, the planar joint comprises a pin-in-slot joint. In some embodiments, at least one joint has one degree of freedom. In some embodiments, the joint has two degrees of freedom. In some embodiments, the joint has more than two degrees of freedom. In some embodiments, the joint has at least one axial linear degree of freedom. In some embodiments, the joint has at least one rotational degree of freedom and one axial degree of freedom. In some embodiments the rotational degree of freedom and the axial linear degree of freedom are on the same plane. In some embodiments, at least one joint prevents swivel motion of the frame and fluid reservoir in respect to each other, about a swivel axis normal to the axis of rotation.


An aspect of some embodiments of the invention relates a self-injector having at least two joints connecting at least a portion of a surface attached to skin and a fluid reservoir one or more of the joints comprises at least two degrees of freedom in respect to the surface, at least one being a rotational degree of freedom. In some embodiments, both degrees of freedom are on a same plane. In some embodiments, the plane is normal to the skin.


An aspect of some embodiments of the invention relates to a path of travel of at least a portion of a needle of a fluid reservoir defined by at least two joints connecting at least a portion of a surface attached to skin and a fluid reservoir with the needle. In some embodiments, one or more of the joints comprises at least two degrees of freedom in respect to the surface, at least one being a rotational degree of freedom. In some embodiments, a path of travel of at least a portion of the needle defined by the two degrees of freedom crosses a surface of the skin along a straight line.


An aspect of some embodiments of the invention relates to a path of travel at which a fluid reservoir needle crosses the surface of skin along a straight line and angled at less than 3 degrees in respect to the straight line. In some embodiments, the angle of penetration of at least a portion of a needle of a fluid reservoir is defined by at least two joints connecting at least a portion of a surface attached to skin and a fluid reservoir with the needle. In some embodiments, one or more of the joints comprises at least two degrees of freedom in respect to the surface, at least one being a rotational degree of freedom. In some embodiments the needle comprises a beveled tip. In some embodiments the bevel at the needle tip faces forward (away from the fluid reservoir). In some embodiments, the needle is curved.


For purposes of better understanding some embodiments of the present invention, as illustrated in FIGS. 3-8 of the drawings, reference is first made to the construction and operation of an auto-injection device as illustrated in FIGS. 1A and 1B, collectively referred to as FIG. 1, which are cross section simplified illustrations of a self-injector as known in the art.


As shown in FIG. 1A, self-injector 102 comprises a fluid reservoir 104 and a needle 106, orientated generally normal to the longitudinal axis of fluid reservoir 104. Fluid reservoir 104 is rotatingly coupled to a base 108 via a hinge 110 that is fixed in place, i.e., immovable from its fixed location. In operation and as shown in FIG. 1B, base 108 is placed against a surface 112 of the skin and fluid reservoir 104 is rotated about hinge 110 in a direction indicated by arrow 150 bringing needle 106 to penetrate surface 112 of the skin at a point of entrance 170.


Upon insertion of needle 106 into the skin, tip 114 of needle 106 follows a curvilinear path indicated by arrow 190 a component of which is an inwardly radial component of movement (see also FIG. 2) directed towards the axis of rotation of the fluid reservoir. Inwardly directed radial movement of needle tip 114 may, in some instances, stretch and possibly tear tissue 116 in the wake of curvilinear path 190 between point of entry 170 and a final resting point 175. As shown in FIG. 1B, tip 114 comprises a beveled opening 118 facing the body of the fluid reservoir or axis of rotation to which it is attached. Along the curvilinear path 190 of needle tip 114 between point of entry 170 and a final resting point 175 tissue may be forced into opening 118 and clog needle tip 114.



FIG. 2 is a simplified diagram that demonstrates formation of a curvilinear path such as path 290 of FIG. 1B. In FIG. 2 a tangential point 202 is connected to a point of rotation (P) via a fixed-length radius (r). Point of rotation (P) is fixed in place, i.e., immovable from its location. When point 202 is moved in a direction indicated by arrow 250 crossing a horizon (h), fixed-length radius (r) and fixed-in-place point of rotation (P) restrict point 202 movement to a curvilinear path 270.


Movement along curvilinear path 270 may include an inwardly radial component 275 of movement, directed towards point of rotation (P). In some cases, point 202 may represent tip 114 of needle 106 and horizon (h) may represent surface 112 of the skin.


Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.


In some self-injectors there is importance to the shape of the path along which the injection needle travels. As explained above, a needle penetrating tissue substantially along a straight (linear) path of travel, minimizing inwardly radial component 275 of movement, may, in some cases, possibly lessen tissue damage such as excessive tissue stretch and possibly tear (e.g., 116, FIG. 1B) along the path of travel through the tissue. As explained above, FIGS. 3A and 3B, collectively referred to as FIG. 3, are simplified diagrams that demonstrate optional mechanisms that convert a path of travel of a tangential point connected to a point of rotation (P) via a radius (r) from a curvilinear path to a substantially straight (linear) path of motion and minimize inwardly radial component 275 of movement. In some embodiments, the tangential point comprises a portion of a needle, the needle being perpendicular to radius (r).


In some embodiments, curvilinear movement of a tangential point 304 from above horizon (h) to below horizon (h) may be converted into linear movement in a direction indicated by arrow 352 along a tangential straight path 306. In some exemplary embodiments shown in FIG. 3A, radius (r) comprises at least one elastic member 308, e.g., a spring that allows radius (r). In some embodiments, elastic member 308 may be a linear elastic member. In some embodiments, elastic member 308 stretches to maintain point 304 on path 306. Alternatively and optionally, in some exemplary embodiments, shown in FIG. 3B, radius (r) has a fixed length and point of rotation (P) is allowed to move closer to path 306 as necessary to maintain point 304 on path 306.


In the examples shown in FIGS. 3 A, 3B and 3C, which are diagrammatic illustrations of spatial orientations of a needle travelling along a path tangential to a circle, point 304 may represent a tip of a needle and horizon (h) may represent surface 112 of the skin. In some examples, a limiting factor, for example, resistance of elastic member 308 (FIG. 3A) or a physical barrier may restrict translation of point 304 to path 306.


On a smaller scale, and as shown in FIG. 3C, and is explained in greater detail elsewhere in this disclosure, in some instances due to mechanical limitations, joints (e.g., the joints mechanism of operation illustrated in FIGS. 3A and 3B) may eliminate inwardly radial component 275 of movement of a tip of a needle travelling along path 306. However and as shown in FIG. 3C, the body of a needle may rotate slightly while travelling along straight path 306 and the tip of the needle (tangential point 403) may still minutely deviate from path 306. In some examples, a limiting factor, for example, resistance of elastic member 308 (FIG. 3 A) or a physical barrier may maintain the angle of needle at point of crossing horizon (h) at less than 3 degrees from path 306. As shown in FIGS. 3A-3C and explained in greater detail elsewhere in the disclosure, in some embodiments, point of rotation (P) comprises a joint that has two or more degrees of freedom in respect to a surface attached to skin, at least one being a rotational degree of freedom. In some embodiments, both degrees of freedom are on a same plane. In some embodiments, the plane is normal to the skin. In some embodiments, the translational degree of freedom defines a straight line. In some embodiments, the translational degree of freedom is parallel to said skin.


As explained elsewhere in this disclosure, user discomfort from an injection may be brought about by mainly the nature of the path along which a needle penetrates the skin and the angle of the needle relative to the path of penetration at which it enters the skin. For example, a needle penetrating skin along a curvilinear path (see also 1B) may rupture skin and subcutaneous tissue causing discomfort to the user. Additionally or alternatively, a needle excessively angled in respect to a straight path of penetration of skin may cause discomfort to a user as well.


Reference is now made to FIGS. 4A, 4B and 4C, collectively referred to as FIG. 4, which are side-view simplified illustrations depicting three successive operative stages of an exemplary embodiment of a self-injector during introduction of a needle thereof into skin. In some embodiments, self-injector 400 is a patch self-injector adhered to the surface of the skin of a user. In some embodiments, the self-injector comprises at least one joint 402/420 that couples surface 404 and a fluid reservoir 408 with at least one needle 410. In some embodiments, frame 404 is attached to skin of a user. In some embodiments, surface 404 comprises a frame. In some embodiments, joint 402/420 has at least one degree of freedom. In some embodiments, joint 402/420 has at least two or more degrees of freedom in respect to surface 404. In some embodiments, at least one of the degrees of freedom is a rotational degree of freedom, for example, rotating fluid reservoir 408 about joint 402/420 bringing needle 410 to cross the surface of skin 412 and penetrate skin 412. In some embodiments, both degrees of freedom are on a same plane normal to skin 412. In some embodiments, at least one degree of freedom comprises translational freedom of movement, for example, moving fluid reservoir 408 and needle 410 optionally axially, in a back and forth direction [i.e., in a direction from the back end (non-needle end) towards the front end (needle-end) of injector 400 and vice versa].


In the exemplary embodiment of FIG. 4 a fluid reservoir 408 is supported by a support plate 406 fitted to support at least fluid reservoir 408 and at least one needle 410. In an exemplary embodiment, self-injector 400 comprises one or more joints 402/420 rotatingly connecting support plate 406 and frame 404. Joint 402 of the embodiment depicted in FIG. 4 comprises at least one first pin 405, attached to support plate 406 and slidably engages frame 404 via an elongated slot 418 in frame 404. Elongated slot may be in a form of a straight line, a curved line, a serpentine line, a sinusoidal line or any geometrical form calculated to bring needle 410 to travel in a straight line and enter the surface of skin 412 at a properly adjusted tilt angle (β) as described elsewhere in the disclosure. In some embodiments, elongated slot 418 is oriented longitudinally, parallel to the long axis of frame 404, long axis of fluid reservoir 408 and surface 412 of the skin, providing first pin 405 with freedom to move, optionally axially, in a back and forth direction [i.e., in a direction from the back end (non-needle end) towards the front end (needle-end) of injector 400 and vice versa]. In some embodiments, pin 405 and elongated slot 418 form a pin-in-slot joint parallel to the long axis of frame 404 on a plane normal to surface 412 of the skin. In some embodiments, pin 405 and elongated slot 418 form a pin-in-slot joint parallel to the long axis of frame 404 on a plane parallel to surface 412 of the skin.


In some embodiments, support plate 406 is fitted to support at least one fluid reservoir 408 having at least one needle 410 projecting from fluid reservoir 408 angled neck 416. In some embodiments, at least a portion of needle 410 is normal to the longitudinal axis of fluid reservoir 408. In some embodiments, at least a portion of needle 410 is normal to the support plate 406.


In the exemplary embodiment showed in FIG. 4, rotation of support plate 406 about joint 402 in respect to frame 404 and in a direction indicated by arrow 450 brings about co-rotation of fluid reservoir 408 supported thereby, moving needle 410 towards surface 412 of the skin. In some embodiments, joint 402 supports forward [i.e., from the back end (non-needle end) towards the front end (needle-end) of injector 400] and backward, optionally axial, movement of fluid reservoir 408 in respect to frame 404.


In some embodiments injector 400 comprises at least a second joint 420 including a second pin 422 attached to support plate 406 and slidably engages frame 404 via an elongated slot 424 in frame 404. In some embodiments, joint 420 restricts the forward and backward, optionally axial movement of joint 402. The level of restriction depends on the angle (a) between paths of translation of joints 402 and 420. In FIG. 4, the paths of translation are defined by elongated slots 418/424 in each of joints 402/420 respectively. In the exemplary embodiment of FIG. 4, elongated slot 424 is oriented along a forwardly declining slope 426 at an angle (a) between 40 and 90, 50 and 80, 60 and 70 degrees more than 90 or less than 40 or intermediate angles between paths of translation of joints 402 and 420. As support plate 406 is rotated about joint 402 in respect to frame 404, elongated slot 424 guides pin 422 along slope 426, which in turn pulls, optionally axially, support plate and first pin 405 forwardly up to a limit defined by angle (a).


Forward movement of support plate 406 and fluid reservoir 408 concurrently with rotation of support plate 406 and fluid reservoir 408 supported thereby in respect to frame 404 contributes to conversion of curvilinear movement of angled neck 416 on the front end (needle-end) of fluid reservoir 408 to linear, tangential movement of needle tip 414 as explained elsewhere in this disclosure. As shown in FIGS. 4A, 4B and 4C, which represent successive stages in introduction of needle tip 414 into the skin as support plate 406 and fluid reservoir 408 continue to be rotated, optionally from an elevated angular state to a final horizontal state parallel to surface 412 of the skin, needle tip 414 travels along a path defined by at least two degrees of freedoms discussed elsewhere in the disclosure and approaches and eventually penetrates surface 412 of the skin. Optionally, needle tip 414 moves along a tangential straight path 452, similar to path 306 of FIGS. 3 A and 3B in a direction indicated by arrow 455.


A potential advantage of the combined action of joints 402/420 is in the formation of a straight path of travel of needle tip 414 through surface 412 of the skin and reducing discomfort to a user during introduction of the needle into the skin.


Reference is now made to FIGS. 5A, 5B, 5C, 5D and 5E, collectively referred to as FIG. 5, which are side view, simplified illustrations of a needle 410 tip 414 demonstrating the effect of an exemplary embodiment of a joint such as that depicted in FIG. 3 on angle of needle at a point of penetration of tip 414 into skin 412.


As described elsewhere in this disclosure, in some embodiments, joints 402/420 may not only reduce inwardly radial component 275 of movement of a tip of a needle but also compensate for a tilt or angle of the body of needle 410 relative to straight path of travel 306. The smaller the angle (β) the less the discomfort experienced by a user at introduction of needle 410 into the skin. As shown in FIG. 5 A, in some embodiments, needle 410 is angled at an angle (β). In some embodiments, angle (β) may be less than 5 degrees, less than 3 degrees, less than 1 degree, more than 5 degrees or an intermediate angle in respect to straight path 452.


In some embodiments, an angle (β) of needle 410 in respect to straight path 452 brings needle tip 414 to minutely deviate from straight path 452. In FIGS. 5A-5E, tip 414 may minutely deviate from path 452 by a distance of deviation (d) due to a change in the angle of the needle in reference to path of travel 452. In some embodiments distance of deviation (d) is measured between point of entry 504 of needle tip 414 into the surface 412 of the skin to the final resting position 506 of tip 412 in the Subcutaneous tissue.


Optionally, to avoid possible clogging of needle opening (as discussed elsewhere in this disclosure) and generation of high back pressure, in some embodiments, a beveled opening 502 of the needle tip 414 faces forward (i.e., away from the body of the fluid reservoir to which it is attached).



FIG. 5B illustrates an exemplary embodiment, in which joints 402/420 are adjusted properly bringing the tilt angle of needle 410 close to parallel to path 452, resulting in minimal deviation (d) of needle tip 414 from path 452 and creating an optimally sized entry hole 506 in surface 412 of the skin. Movement of needle tip 414 from point of entry 504 to final resting position 575 compresses tissue 508 behind (i.e., on the side of fluid reservoir 418 body) of tip 414 and stretches tissue 510 ahead (i.e., on the side away from fluid reservoir 418 body) and away from tip 414 opening 502 reducing occurrence of back pressure resisting injection and occlusion of needle tip 414 opening.


In some embodiments and as shown in FIG. 5C, when the tilt angle (β) of needle 410 is adjusted properly it forms an optimally sized entry hole 506 upon arrival at its final resting position 575 in the injection site, having a diameter (Φ) which is between 1.5 and 2.5 times the diameter (Φ′) of needle 410 e.g., Φ=1.5Φ′, Φ=2Φ′, Φ=2.25Φ′, Φ=2.35Φ′, Φ=2.5Φ′ or an intermediate multiplier.


A potential advantage of an optimally sized entry hole 506 is in that pain associated with tearing of the surface of the skin is minimal and the small diameter of the opening in the surface of the skin throughout the injection period minimizes chances of leakage of an injectable being injected up to and outside the surface of the skin.


In some embodiments and as depicted in FIG. 5D, overcompensation of joints 402/420 (i.e., excessive forward movement of joint 402) may bring needle 414 to tilt excessively backwards (i.e., sloping towards body of fluid reservoir 418), compressing tissue 510 ahead (i.e., on the side away from fluid reservoir 418 body) of tip 414 and stretching tissue 508 behind (i.e., on the fluid reservoir 418 body side) of tip 414 increasing occurrence of back pressure resisting injection and occluding needle tip 414 opening of bevel 502 as indicated by arrow 552.


In some embodiments and as depicted in FIG. 5E, under compensation of joints 402/420 (i.e., insufficient forward movement of joint 402) may bring needle 414 to tilt excessively forwards (i.e., sloping away from body of fluid reservoir 418), stretching surface 412 of the skin and enlarging a hole 512 created by penetration of skin 412. A large penetration hole may allow injected material to leak out of the injection site as depicted by arrow 554.


In some embodiments, joints 402/420 are oriented so that at least the proximal (upper) end 525 (FIG. 5A) of bevel 502 follows straight linear path 452. In some embodiments, joints 402/420 are oriented so that at least the central longitudinal axis of needle 410 follows straight linear path 452. Once a crossing point between path 452 and surface 412 of the skin (i.e., point of entry 504 of needle tip 414 into the surface 412 of the skin) is known, joints 402/420 may be set so that forward movement of at least portions of joints 402/420/808 maintain needle 410 tip 412 on path 452 and keeps angle of needle 410 as parallel as possible to path 452 bringing tip 412 to enter surface 412 of skin at desired point of entry 504.


A potential advantage of the combined action of at least joints 402/420 is in the formation of a straight path of travel of needle tip 414 through surface 412 of the skin, keeping angle of needle 410 as parallel as possible to the path of travel and reducing discomfort to a user during introduction of the needle into the skin.


The smaller the angle (β) the less the discomfort experienced by a user at introduction of needle 410 into the skin. In some embodiments, distance of deviation (d) of needle tip 414 from path 452 resulting from tilt of needle 410 is between 0.1 mm-1.0 mm, 0.2 mm-0.5 mm, 0.3 mm-0.4 mm, less than 0.1 mm, more than 1.0 mm or any intermediate distance.



FIGS. 5F and 5G are graph that show the effect of injector joint adjustment e.g., compensation, on back pressure on the bevel of a needle resulting from a path traveled by a needle entering the skin. FIG. 5F depicts high back pressure (resistance) to an injection of an injectable into the skin resulting from a lack of adjustment e.g., compensation of a path of travel and/or angle of tilt of a needle entering the skin (also see FIG. 5D). As shown in FIG. 5F, after about 51 seconds the injection was stopped and a second attempt was made at 86 seconds. In both cases resistance to the injection increased initially exponentially between Opsi and 33 psi and then logarithmically between 24 psi and 43-45 psi.


However, with compensation applied, as shown in FIG. 5G, a minor initial peak in backpressure between seconds 15 and 29 is followed by a low plateau throughout the injection period remaining at a level of 3-4 psi. FIGS. 5F and 5G show that proper adjustment compensation of the needle path of travel and angle of tilt when crossing the surface of skin can reduce backpressure to a level 80-85% of non-compensated needle path of travel and angle of tilt.


Reference is now made to FIGS. 6A, 6B and 6C, collectively referred to as FIG. 6, which are side-view partial cross section view simplified illustrations depicting three successive operative stages of an exemplary embodiment of a self-injector during introduction of a needle thereof into skin. Reference is also made to FIG. 6D, which is a cross-section view along a W-W section, simplified illustration of a joint 602 joint view from a direction indicated by arrow 650.


In some embodiments, self-injector 600 is a patch self-injector that is adhered to the surface of the skin of a user. In the exemplary embodiment of FIG. 6, self-injector 600 comprises one or more joints 602 and rotatingly connects fluid reservoir 408 and frame 404. Additionally and optionally, joint 402 rotatingly connects support plate 406 and frame 404.


In some embodiments, joint 602 comprises at least one slotted cylinder 604 coupled to frame 404 and sized to slidingly and optionally partially swivelly accommodate angled head 416 plunger 606. In some embodiments cylinder 602 is slotted along a back aspect (facing fluid reservoir 408). In some embodiments a slot 608 is fitted to allow angled head 416 freedom to move up and down cylinder 604 as self-injector 600 is rotated optionally from an elevated angular state to a final horizontal state, parallel to surface 412 of the skin. Optionally, in some embodiments, slot 608 is fitted to allow angled head 416 freedom to partially swivel within cylinder 604. In some embodiments, cylinder 602 wall is curved to slidingly accommodate both the curvilinear path of angled head 416 and needle tip 414.


As support plate 406 and fluid reservoir 408 rotate in respect to frame 404, optionally from an elevated angular state to a final horizontal state, parallel to surface 412 of the skin, plunger 606 slidingly engages cylinder 604 wall and is guided along cylinder 604 wall so that needle tip 414 approaches and eventually penetrates surface 412 of the skin, optionally moving along a tangential straight path 452, generally perpendicular to surface 412 of the skin and in a direction indicated by arrow 455. Optionally, movement of plunger 606 along curved cylinder 604 wall may result in forward movement of fluid reservoir 408 and of support plate 406 attached thereto.


In some embodiments, Plunger 606 is made of a resilient material i.e., a soft polymer or elastomer (e.g., Silicone).


Optionally, the exemplary embodiment shown in FIG. 6 may include a joint similar to joint 402 the operation thereof is explained in reference to FIG. 4 and will not be repeated.


Reference is now made to FIGS. 7 A, 7B and 7C, collectively referred to as FIG. 7, which are side-view simplified illustrations depicting three successive operative stages of an exemplary embodiment of a self-injector during introduction of a needle thereof into skin. Reference is also made to FIG. 7D, which is a cross-section view along a W-W section, simplified illustration of a joint 702 view from a direction indicated by arrow 750.


In some embodiments, self-injector 700 is a patch self-injector that is adhered to the surface of the skin of a user. In the exemplary embodiment of FIG. 7, self-injector 700 comprises one or more joints 702 and rotatingly connects fluid reservoir 408 and frame 404. Additionally and optionally, joint 402 rotatingly connects support plate 406 and frame 404.


In some embodiments, joint 702 comprises at least a portion of a notional cylinder wall 704 having at least one slot, coupled to frame 404 and sized to slidingly accommodate angled head 416. In the exemplary embodiment of FIG. 7, notional cylinder wall 704 comprises at least one pin 722 attached to angled head 416 and slidably engages cylinder 704 via an elongated slot 724 along notional cylinder wall 704. In the exemplary embodiment of FIG. 7, elongated slot 724 is curved to allow notional cylinder wall 704 to slidingly accommodate both the curvilinear path of angled head 416 and needle tip 414.


As support plate 406 and fluid reservoir 408 rotate in respect to frame 404, optionally from an elevated angular state to a final horizontal state, parallel to surface 412 of the skin, pin 722 slidingly engages notional cylinder wall 704 slot 724 and is guided along slot 724 so that needle tip 414 approaches and eventually penetrates surface 412 of the skin, optionally moving along a tangential straight path 452, generally perpendicular to surface 412 of the skin. Optionally, movement of pin 722 along curved slot 724 may result in forward movement of fluid reservoir 408 and of support plate 406 attached thereto.


Optionally, the exemplary embodiment shown in FIG. 7 may include a joint similar to joint 402 the operation thereof is explained elsewhere in this disclosure and will not be repeated.


Reference is now made to FIGS. 8A, and 8B, which are side view and top view simplified illustrations of an exemplary embodiment of a self-injector. In some embodiments, self-injector 800 is a patch self-injector that is adhered to the surface of the skin of a user.


The exemplary embodiments illustrated in FIGS. 8A, 8B and 8C include a joint comprises one or more joint 802 similar to joint 702 that rotatingly connects fluid reservoir 408 and frame 404. The operation of joint 702 is explained elsewhere in this disclosure and will not be repeated.



FIGS. 8 A and 8B depict an exemplary embodiment of a self-injector which comprises at least one joint 802 that comprises a groove 804 in frame 404 and a protrusion 806 attached to support plate 406 and slidingly accommodated within groove 804. In some embodiments groove 804 is in support plate 406 and protrusion 806 is attached to frame 404. In some embodiments, joint 802 is located between surfaces of frame 404 and support plate 406. In some embodiments, joint 802 is located between surfaces of frame 404 and support plate 406 that are parallel to surface 412 of the skin. In the exemplary embodiment of FIGS. 8A and 8B, protrusion 806 is in a form of a fin, however, protrusion 806 may have any geometrical shape suitable for sliding engagement with groove 804. Groove 804 is disposed parallel to the longitudinal axis of fluid reservoir 408.


As support plate 406 and fluid reservoir 408 rotate in respect to frame 404, optionally from an elevated angular state to a final horizontal state, parallel to surface 412 of the skin, protrusion 806 slidingly engages groove 804 and is guided along groove 804. In some embodiments, the width of groove 804 determines the degree at which support plate 406 is allowed to swivel in respect to frame 404 as fluid reservoir 408 and support plate 406 are pulled forward by movement of joint 602 pin 622 along curved slot 624 as explained in reference to FIG. 6.


In an exemplary embodiment, shown in FIG. 8C, injector 800 comprises at least one joint 802 similar to joint 602 that rotatingly connects fluid reservoir 408 and frame 404. The operation of joint 602 is explained elsewhere in this disclosure and will not be repeated. In some embodiments, injector 800 comprises one or more joints 808 between support plate 406 and frame 404. In some embodiments, joint 808 comprises one or more elastic members 810. In the exemplary embodiment shown in FIG. 8C the elastic member is represented by a spring.


In some embodiments, as support plate 406 and fluid reservoir 408 are rotated, optionally from an elevated angular state to a final horizontal state, parallel to surface 412 of the skin, elastic member 810 dampens forward movement as well as swivel of fluid reservoir 408 and support plate 406 relative to frame 404 as they are pulled forward by movement of joint 602 pin 622 along curved slot 624 as explained in reference to FIG. 6. In the exemplary embodiment illustrated in FIG. 8C, fluid reservoir 408 and support plate 406 are in a final horizontal state (FIG. 6C) as evident by a gap 850 formed between support plate 406 and frame 404 as a result of fluid reservoir 408 and support plate 406 has been pulled forward by joint 802.


In some exemplary embodiments joint 808 may be a spring in a compressed state when fluid reservoir 408 and support plate 406 are in their elevated angular state. In such a configuration, once the injection process is completed and fluid reservoir 408 and support plate 406 are rotated back to their elevated angular state, joint 808 elastic members 810 may assist in re-approximating fluid reservoir 408 and support plate 406 and frame 404. In some embodiments joint 808 may be a spring in a resting state when fluid reservoir 408 and support plate 406 are in their elevated angular state.


Reference is now made to FIGS. 9A and 9B, which are side view simplified illustrations of an exemplary embodiment of a self-injector. In some embodiments, self-injector 900 comprises a patch self-injector adhered to the surface of the skin of a user. In some embodiments, the self-injector comprises at least one joint 902/920 that couples a surface 904 and a fluid reservoir 908 with at least one needle 910. In some embodiments, frame surface 904 comprises a portion of a frame 906 attached to skin of a user. In some embodiments, joint 902/920 has at least one degree of freedom. In some embodiments, joint 902/920 has at least two or more degrees of freedom in respect to frame surface 904. In some embodiments, at least one of the degrees of freedom is a rotational degree of freedom, for example, rotating fluid reservoir 908 bringing needle 910 to cross surface of skin 412. In some embodiments, both degrees of freedom are on a same plane normal to skin 412. In some embodiments, at least one degree of freedom comprises translational freedom of movement, for example, moving fluid reservoir 908 and needle 910 optionally axially, in a back and forth direction [i.e., in a direction from the back end (non-needle end) towards the front end (needle-end) of injector 900 and vice versa].


In the exemplary embodiment of FIGS. 9A and 9B a fluid reservoir 908, e.g., a syringe, vial, cartridge, is supported by a support plate 906 fitted to support at least fluid reservoir 908 and at least one needle 910. In an exemplary embodiment, self-injector 900 comprises one or more joints 902/920 rotatingly connecting support plate 906 and frame 904. Joint 902 of the embodiment depicted in FIGS. 9A and 9B comprises at least one joint comprising at least two interlocking arms.


In some embodiments, support plate 906 is fitted to support at least one fluid reservoir 908 having at least one needle 910 projecting from fluid reservoir 908 angled neck 916. In some embodiments, at least a portion of needle 910 is normal to the longitudinal axis of fluid reservoir 908. In some embodiments, at least a portion of needle 910 is normal to the support plate 906.


In some embodiments injector 900 comprises at least a second joint 920 including a pin 922 attached to support plate 906 and slidably engages frame 904 via an elongated slot 924 in frame 904. Elongated slot may be in a form of a straight line, a curved line, a serpentine line, a sinusoidal line or any geometrical form calculated to bring needle 910 to travel in a straight line and enter the surface of skin 412 at a properly adjusted tilt angle (β) as described elsewhere in the disclosure.


In some embodiments, joint 920 restricts movement of joint 902. The level of restriction depends on the angle (a) between paths of translation of joints 902 and 920. In FIGS. 9A and 9B, the paths of translation of joints 902/920 are defined by elongated slot 918 in joint 920, length of one or more interlocking arms 950 and rotational limit of the pivot points coupling interlocking arms to each other and to support plate 906 and frame 904. In the exemplary embodiment of FIGS. 9A and 9B, elongated slot 924 is oriented along a forwardly declining slope 926 at an angle (a) between 40 and 90, 50 and 80, 60 and 70 degrees more than 90 or less than 40 or intermediate angles between paths of translation of joints 902 and 920. As support plate 906 is rotated about joint 902 in respect to frame 904, elongated slot 924 guides pin 922 along slope 926, which in turn pulls support plate and first joint 902 forwardly up to a limit defined by angle (a).


A potential advantage of the combined action of joints 902/920 is in the formation of a straight path of travel of needle tip 914 through surface 412 of the skin and reducing discomfort to a user during introduction of the needle into the skin.


The terms “comprises”, “comprising”, “includes”, “including”, “has”, “having” and their conjugates mean “including but not limited to”.


The term “consisting of” means “including and limited to”.


The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.


As used herein, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.


Throughout this application, embodiments of this invention may be presented with reference to a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as “from 1 to 6” should be considered to have specifically disclosed subranges such as “from 1 to 3”, “from 1 to 4”, “from 1 to 5”, “from 2 to 4”, “from 2 to 6”, “from 3 to 6”, etc.; as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.


Whenever a numerical range is indicated herein (for example “10-15”, “10 to 15”, or any pair of numbers linked by these another such range indication), it is meant to include any number (fractional or integral) within the indicated range limits, including the range limits, unless the context clearly dictates otherwise. The phrases “range/ranging/ranges between” a first indicate number and a second indicate number and “range/ranging/ranges from” a first indicate number “to”, “up to”, “until” or “through” (or another such range-indicating term) a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numbers therebetween.


Unless otherwise indicated, numbers used herein and any number ranges based thereon are approximations within the accuracy of reasonable measurement and rounding errors as understood by persons skilled in the art.


It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.


Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.


All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.

Claims
  • 1. An injector, comprising a fluid reservoir connected to a needle and supported by a support plate;a frame having a surface configured for attachment to skin, the frame being coupled to the support plate by at least a first joint and a second joint;a first elongate slot attached to the frame and a first pin attached to the support plate, the first pin being slidably and rotatably engaged with the first elongate slot defining a first joint;a second elongate slot attached to the frame and a second pin attached to the support plate, the second pin being slidably engaged with the second elongate slot defining a second joint;wherein the first and second joints each permit translation of the support plate with respect to the frame, and the first joint also permits rotation of the support plate with respect to the frame.
  • 2. The injector of claim 1, wherein the first elongate slot is formed in the frame.
  • 3. The injector of claim 1, wherein the first elongate slot extends in a direction parallel with a long axis of the fluid reservoir, thereby permitting the first pin to translate along the long axis.
  • 4. The injector of claim 1, wherein the first pin extends in a direction parallel to the frame.
  • 5. The injector of claim 1, wherein the second elongate slot angularly projects from the frame.
  • 6. The injector of claim 5, wherein the second elongate slot is oriented along a forwardly declining slope relative to the first elongate slot.
  • 7. The injector of claim 5, wherein the second elongate slot defines an included angle with the first elongate slot of approximately between 40° and approximately 90°.
  • 8. The injector of claim 1, wherein the second pin is oriented substantially parallel to the frame.
  • 9. The injector of claim 1, wherein the second joint is positioned closer to the needle than the first joint.
  • 10. The injector of claim 1, wherein when the support plate is rotated with respect to the frame and when the needle reaches a point of penetration, at least a portion of the needle is angled less than 5 degrees deviated from a straight line normal to the surface of the frame.
  • 11. The injector of claim 1, wherein at least a portion of a path of translation of the first pin is curved.
  • 12. The injector of claim 1, wherein at least one of the first and second joints is located between a rear, non-needle end of the fluid reservoir and a front, needle end of the fluid reservoir.
  • 13. The injector of claim 1, wherein at least a portion of the needle is curved.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 16/448,517, filed Jun. 21, 2019, which is a divisional of U.S. application Ser. No. 15/766,437, filed Apr. 6, 2018, issued as U.S. Pat. No. 10,369,289 on Aug. 6, 2019, which is a section 371 of International Application No. PCT/US16/56227, filed Oct. 10, 2016, which was published Apr. 13, 2017 under International Publication No. WO 2017/062935 A1, which is a continuation of U.S. application Ser. No. 15/204,542, filed Jul. 7, 2016, which claims the benefit of U.S. Provisional Application No. 62/281,536, filed Jan. 21, 2016 and U.S. Provisional Application 62/284,806, filed Oct. 9, 2015; and a continuation of U.S. application Ser. No. 15/269,248, filed Sep. 19, 2016, the disclosures of which are incorporated herein by reference.

US Referenced Citations (975)
Number Name Date Kind
232432 Allison Sep 1880 A
1125887 Schimmel Jan 1915 A
1321550 Frank et al. Nov 1919 A
1704921 Nicoll Mar 1929 A
1795530 Cowan et al. Mar 1931 A
1795630 Wilson Mar 1931 A
2453590 Poux Nov 1948 A
2589426 Ogle Mar 1952 A
2677373 George May 1954 A
2702547 Glass Feb 1955 A
2860635 Wilburn Nov 1958 A
3203269 Perrine Aug 1965 A
3212685 James et al. Oct 1965 A
3585439 Schneeberger Jun 1971 A
3623474 Heilman et al. Nov 1971 A
3705582 Stumpf et al. Dec 1972 A
3708945 Klettke Jan 1973 A
3794028 Mueller et al. Feb 1974 A
3834387 Brown Sep 1974 A
3994295 Wulff Nov 1976 A
4085747 Lee Apr 1978 A
4189065 Herold Feb 1980 A
4195636 Behnke Apr 1980 A
4218724 Kaufman Aug 1980 A
4254768 Ty Mar 1981 A
4273122 Whitney et al. Jun 1981 A
4300554 Hessberg et al. Nov 1981 A
4324262 Hall Apr 1982 A
4403987 Gottinger Sep 1983 A
4425120 Sampson et al. Jan 1984 A
4435173 Siposs et al. Mar 1984 A
4465478 Sabelman et al. Aug 1984 A
4502488 Degironimo et al. Mar 1985 A
4504263 Steuer et al. Mar 1985 A
4549554 Markham Oct 1985 A
4564054 Gustavsson Jan 1986 A
4565543 Bekkering et al. Jan 1986 A
4583974 Kokernak Apr 1986 A
4585439 Michel Apr 1986 A
4599082 Grimard Jul 1986 A
4601702 Hudson Jul 1986 A
4636201 Ambrose et al. Jan 1987 A
4664654 Strauss May 1987 A
4685903 Cable et al. Aug 1987 A
4695274 Fox Sep 1987 A
4698055 Sealfon Oct 1987 A
4702738 Spencer Oct 1987 A
4704105 Adorjan et al. Nov 1987 A
4710178 Henri et al. Dec 1987 A
4729208 Galy et al. Mar 1988 A
4735311 Lowe et al. Apr 1988 A
4737144 Choksi Apr 1988 A
4772272 Mcfarland Sep 1988 A
4810215 Kaneko Mar 1989 A
4810249 Haber et al. Mar 1989 A
4813426 Haber et al. Mar 1989 A
4840185 Hernandez Jun 1989 A
4850966 Grau et al. Jul 1989 A
4861341 Woodburn Aug 1989 A
4863434 Bayless Sep 1989 A
4867743 Vaillancourt Sep 1989 A
4874383 Mcnaughton Oct 1989 A
4882575 Kawahara Nov 1989 A
4886499 Cirelli et al. Dec 1989 A
4892521 Laico et al. Jan 1990 A
4897083 Martell Jan 1990 A
4900310 Ogle, II Feb 1990 A
4915702 Haber Apr 1990 A
4919569 Wittenzellner Apr 1990 A
4919596 Slate et al. Apr 1990 A
4923446 Page et al. May 1990 A
4929241 Kulli May 1990 A
4950241 Ranford Aug 1990 A
4950246 Muller Aug 1990 A
4957490 Byrne et al. Sep 1990 A
4964866 Szwarc Oct 1990 A
4994045 Ranford Feb 1991 A
4998924 Ranford Mar 1991 A
5019051 Hake May 1991 A
5051109 Simon Sep 1991 A
5062828 Waltz Nov 1991 A
D322671 Szwarc Dec 1991 S
5088988 Talonn et al. Feb 1992 A
5109850 Blanco et al. May 1992 A
5112317 Michel May 1992 A
5114406 Gabriel et al. May 1992 A
5127910 Talonn et al. Jul 1992 A
5131816 Brown et al. Jul 1992 A
5147326 Talonn et al. Sep 1992 A
5156599 Ranford et al. Oct 1992 A
5190521 Hubbard et al. Mar 1993 A
5217437 Talonn et al. Jun 1993 A
5246670 Haber et al. Sep 1993 A
5254096 Rondelet et al. Oct 1993 A
5267977 Feeney, Jr. Dec 1993 A
5269762 Armbruster et al. Dec 1993 A
5275582 Wimmer Jan 1994 A
5282593 Fast Feb 1994 A
5295966 Stern et al. Mar 1994 A
5298023 Haber et al. Mar 1994 A
5300045 Plassche, Jr. Apr 1994 A
5318522 D'Antonio Jun 1994 A
5338311 Mahurkar Aug 1994 A
5342313 Campbell et al. Aug 1994 A
5348544 Sweeney et al. Sep 1994 A
5366498 Brannan et al. Nov 1994 A
5376785 Chin et al. Dec 1994 A
5383865 Michel Jan 1995 A
D356150 Duggan et al. Mar 1995 S
5415645 Friend et al. May 1995 A
5456360 Griffin Oct 1995 A
5478315 Brothers et al. Dec 1995 A
5478316 Bitdinger et al. Dec 1995 A
5482446 Williamson et al. Jan 1996 A
5496274 Graves et al. Mar 1996 A
5501665 Jhuboo et al. Mar 1996 A
5505709 Funderburk et al. Apr 1996 A
5562624 Righi et al. Oct 1996 A
5562686 Sauer et al. Oct 1996 A
5593390 Castellano et al. Jan 1997 A
5609580 Kwiatkowski et al. Mar 1997 A
5611785 Mito et al. Mar 1997 A
5616132 Newman Apr 1997 A
5624400 Firth et al. Apr 1997 A
5637095 Nason et al. Jun 1997 A
5643218 Lynn et al. Jul 1997 A
5645530 Boukhny et al. Jul 1997 A
5645955 Maglica Jul 1997 A
5647853 Feldmann et al. Jul 1997 A
5658256 Shields Aug 1997 A
5662678 Macklin Sep 1997 A
5672160 Oesterlind et al. Sep 1997 A
5690618 Smith et al. Nov 1997 A
5697908 Imbert et al. Dec 1997 A
5697916 Schraga Dec 1997 A
5725500 Micheler Mar 1998 A
5728075 Levander Mar 1998 A
D393314 Meisner et al. Apr 1998 S
5741275 Wyssmann Apr 1998 A
5766186 Faraz et al. Jun 1998 A
5776103 Kriesel et al. Jul 1998 A
5795675 Maglica Aug 1998 A
5800420 Gross et al. Sep 1998 A
5807375 Gross et al. Sep 1998 A
5810167 Fujii Sep 1998 A
5810784 Tamaro Sep 1998 A
5814020 Gross Sep 1998 A
5830187 Kriesel et al. Nov 1998 A
5836920 Robertson Nov 1998 A
5848991 Gross et al. Dec 1998 A
5851197 Marano et al. Dec 1998 A
5858001 Tsais Jan 1999 A
5858008 Capaccio Jan 1999 A
5868710 Battiato et al. Feb 1999 A
5893842 Imbert Apr 1999 A
5894015 Rechtin Apr 1999 A
5919167 Mulhauser et al. Jul 1999 A
5926596 Edwards et al. Jul 1999 A
5931814 Alex et al. Aug 1999 A
5941850 Shah et al. Aug 1999 A
5944699 Barrelle et al. Aug 1999 A
5948392 Haslwanter et al. Sep 1999 A
5954697 Srisathapat et al. Sep 1999 A
5957895 Sage et al. Sep 1999 A
5968011 Larsen et al. Oct 1999 A
5989221 Hjertman Nov 1999 A
5993423 Choi Nov 1999 A
6004296 Jansen et al. Dec 1999 A
6004297 Steenfeldt-Jensen et al. Dec 1999 A
6033245 Zamkovoy Mar 2000 A
6033377 Rasmussen et al. Mar 2000 A
6045533 Kriesel et al. Apr 2000 A
6064797 Crittendon et al. May 2000 A
6074369 Sage et al. Jun 2000 A
6162197 Mohammad Dec 2000 A
6186979 Dysarz Feb 2001 B1
6186982 Gross Feb 2001 B1
6189292 Odell et al. Feb 2001 B1
6200289 Hochman et al. Mar 2001 B1
6200296 Dibiasi et al. Mar 2001 B1
6224569 Brimhall May 2001 B1
6248093 Moberg Jun 2001 B1
6270481 Mason et al. Aug 2001 B1
6277095 Kriesel et al. Aug 2001 B1
6277098 Klitmose et al. Aug 2001 B1
6277099 Strowe et al. Aug 2001 B1
6287283 Ljunggreen et al. Sep 2001 B1
6293925 Safabash et al. Sep 2001 B1
6302633 Poe Oct 2001 B1
6336729 Pavelle et al. Jan 2002 B1
6345968 Shupe Feb 2002 B1
6362591 Moberg Mar 2002 B1
6377848 Garde et al. Apr 2002 B1
6391005 Lum et al. May 2002 B1
6423029 Elsberry Jul 2002 B1
D461243 Niedospial Aug 2002 S
D465026 May et al. Oct 2002 S
6458102 Mann et al. Oct 2002 B1
6485461 Mason et al. Nov 2002 B1
6485465 Moberg et al. Nov 2002 B2
6500150 Gross et al. Dec 2002 B1
6503231 Prausnitz et al. Jan 2003 B1
6511336 Turek et al. Jan 2003 B1
6517517 Farrugia et al. Feb 2003 B1
D471274 Diaz et al. Mar 2003 S
D471983 Hippolyte et al. Mar 2003 S
6554800 Nezhadian et al. Apr 2003 B1
6555986 Moberg Apr 2003 B2
6558351 Steil et al. May 2003 B1
6565541 Sharp May 2003 B2
6585695 Adair et al. Jul 2003 B1
6589229 Connelly et al. Jul 2003 B1
6595956 Gross et al. Jul 2003 B1
6595960 West et al. Jul 2003 B2
6645181 Lavi et al. Nov 2003 B1
6652482 Hochman Nov 2003 B2
6656158 Mahoney et al. Dec 2003 B2
6656159 Flaherty Dec 2003 B2
6659980 Moberg et al. Dec 2003 B2
6673033 Sciulli et al. Jan 2004 B1
6679862 Diaz et al. Jan 2004 B2
6685678 Evans et al. Feb 2004 B2
6689118 Alchas et al. Feb 2004 B2
6699218 Flaherty et al. Mar 2004 B2
6719141 Heinz et al. Apr 2004 B2
6722916 Buccinna et al. Apr 2004 B2
6743211 Prausnitz et al. Jun 2004 B1
6749587 Flaherty Jun 2004 B2
6752783 Hung et al. Jun 2004 B2
6752787 Causey et al. Jun 2004 B1
6767336 Kaplan Jul 2004 B1
6768425 Flaherty et al. Jul 2004 B2
6786890 Preuthun et al. Sep 2004 B2
6800071 Mcconnell et al. Oct 2004 B1
6805687 Dextradeur et al. Oct 2004 B2
6817990 Yap et al. Nov 2004 B2
6824529 Gross et al. Nov 2004 B2
6843782 Gross et al. Jan 2005 B2
6854620 Ramey Feb 2005 B2
6905298 Haring Jun 2005 B1
6907679 Yarborough et al. Jun 2005 B2
6908452 Diaz et al. Jun 2005 B2
6960192 Flaherty et al. Nov 2005 B1
6979316 Rubin et al. Dec 2005 B1
6997727 Legrady et al. Feb 2006 B1
7001360 Veasey et al. Feb 2006 B2
7004104 Kundus Feb 2006 B1
7004929 McWethy et al. Feb 2006 B2
7025226 Ramey Apr 2006 B2
7033338 Vilks et al. Apr 2006 B2
7034223 Fan et al. Apr 2006 B2
7048715 Diaz et al. May 2006 B2
7060054 Nissels Jun 2006 B2
7060059 Keith et al. Jun 2006 B2
7063684 Moberg Jun 2006 B2
7066909 Peter et al. Jun 2006 B1
7094221 Veasey et al. Aug 2006 B2
7097637 Triplett et al. Aug 2006 B2
7112187 Karlsson Sep 2006 B2
7128727 Flaherty et al. Oct 2006 B2
7144384 Gorman et al. Dec 2006 B2
7193521 Moberg et al. Mar 2007 B2
D544092 Lewis Jun 2007 S
7225694 Said Jun 2007 B2
7247149 Beyerlein Jul 2007 B2
7250037 Shermer et al. Jul 2007 B2
7267669 Staunton et al. Sep 2007 B2
RE39923 Blom Nov 2007 E
7291132 Deruntz et al. Nov 2007 B2
7291159 Schmelzeisen-Redeker et al. Nov 2007 B2
7303549 Flaherty et al. Dec 2007 B2
7306578 Gray et al. Dec 2007 B2
7326194 Zinger et al. Feb 2008 B2
7344385 Chen Mar 2008 B2
7364570 Gerondale et al. Apr 2008 B2
7377912 Graf et al. May 2008 B2
7390312 Barrelle Jun 2008 B2
7390314 Stutz et al. Jun 2008 B2
7407493 Cane Aug 2008 B2
7418880 Smith Sep 2008 B1
D578210 Muta et al. Oct 2008 S
7442186 Blomquist Oct 2008 B2
7455663 Bikovsky Nov 2008 B2
7465290 Reilly Dec 2008 B2
7468055 Prais et al. Dec 2008 B2
7488181 Van Feb 2009 B2
7497842 Diaz et al. Mar 2009 B2
7500963 Westbye et al. Mar 2009 B2
7501587 English Mar 2009 B2
7503786 Kato et al. Mar 2009 B2
7530964 Lavi et al. May 2009 B2
7540858 Dibiasi Jun 2009 B2
7547281 Hayes et al. Jun 2009 B2
7565208 Harris et al. Jul 2009 B2
7569050 Moberg et al. Aug 2009 B2
D600341 Loerwald Sep 2009 S
7585287 Bresina et al. Sep 2009 B2
7588559 Aravena et al. Sep 2009 B2
7589974 Grady et al. Sep 2009 B2
D602155 Foley et al. Oct 2009 S
D602586 Foley et al. Oct 2009 S
7597682 Moberg Oct 2009 B2
D604835 Conley Nov 2009 S
7611491 Pickhard Nov 2009 B2
7621893 Moberg et al. Nov 2009 B2
7628770 Ethelfeld Dec 2009 B2
7628772 Mcconnell et al. Dec 2009 B2
7628782 Adair et al. Dec 2009 B2
7637891 Wall Dec 2009 B2
7637899 Woolston et al. Dec 2009 B2
7641649 Moberg et al. Jan 2010 B2
7658734 Adair et al. Feb 2010 B2
7660627 Mcnichols et al. Feb 2010 B2
7678079 Shermer et al. Mar 2010 B2
7682338 Griffin Mar 2010 B2
7686787 Moberg et al. Mar 2010 B2
7699829 Harris et al. Apr 2010 B2
7699833 Moberg et al. Apr 2010 B2
7704088 Sakamoto Apr 2010 B2
7704227 Moberg et al. Apr 2010 B2
7704229 Moberg et al. Apr 2010 B2
7704231 Pongpairochana et al. Apr 2010 B2
7708717 Estes et al. May 2010 B2
7713238 Mernoe May 2010 B2
7713240 Istoc et al. May 2010 B2
7717903 Estes et al. May 2010 B2
7717913 Novak et al. May 2010 B2
7722574 Toman et al. May 2010 B2
7736333 Gillespie, III Jun 2010 B2
7736344 Moberg et al. Jun 2010 B2
7744589 Mounce et al. Jun 2010 B2
7749194 Edwards et al. Jul 2010 B2
7758548 Gillespie et al. Jul 2010 B2
7758550 Bollenbach et al. Jul 2010 B2
7766867 Lynch et al. Aug 2010 B2
7766873 Moberg et al. Aug 2010 B2
7776030 Estes et al. Aug 2010 B2
7780637 Jerde et al. Aug 2010 B2
7789857 Moberg et al. Sep 2010 B2
7794426 Briones et al. Sep 2010 B2
7794427 Estes et al. Sep 2010 B2
7801599 Young et al. Sep 2010 B2
7806868 De et al. Oct 2010 B2
7828528 Estes et al. Nov 2010 B2
7837659 Bush et al. Nov 2010 B2
7846132 Gravesen et al. Dec 2010 B2
7854723 Hwang et al. Dec 2010 B2
7857131 Vedrine Dec 2010 B2
7879025 Jacobson et al. Feb 2011 B2
7892206 Moberg et al. Feb 2011 B2
7901382 Daily et al. Mar 2011 B2
7905867 Veasey et al. Mar 2011 B2
7918825 O'Connor et al. Apr 2011 B2
7935104 Yodat et al. May 2011 B2
7935105 Miller et al. May 2011 B2
7938803 Mernoe et al. May 2011 B2
7955305 Moberg et al. Jun 2011 B2
7967784 Pongpairochana et al. Jun 2011 B2
7967795 Cabiri Jun 2011 B1
7976514 Abry et al. Jul 2011 B2
7981105 Adair et al. Jul 2011 B2
7988683 Adair et al. Aug 2011 B2
7993300 Nyholm et al. Aug 2011 B2
7993301 Boyd et al. Aug 2011 B2
7998111 Moberg et al. Aug 2011 B2
7998131 Adair et al. Aug 2011 B2
8002754 Kawamura et al. Aug 2011 B2
8021357 Tanaka et al. Sep 2011 B2
8025658 Chong et al. Sep 2011 B2
8029469 Ethelfeld Oct 2011 B2
8034019 Nair et al. Oct 2011 B2
8034026 Grant et al. Oct 2011 B2
8038666 Triplett et al. Oct 2011 B2
8057431 Woehr et al. Nov 2011 B2
8057436 Causey et al. Nov 2011 B2
8062253 Nielsen et al. Nov 2011 B2
8062255 Brunnberg et al. Nov 2011 B2
8062257 Moberg et al. Nov 2011 B2
8065096 Moberg et al. Nov 2011 B2
8066694 Wagener Nov 2011 B2
D650079 Presta et al. Dec 2011 S
D650903 Kosinski et al. Dec 2011 S
8086306 Katzman et al. Dec 2011 B2
D652503 Cameron et al. Jan 2012 S
8105279 Mernoe et al. Jan 2012 B2
8105293 Pickhard Jan 2012 B2
8114046 Covino et al. Feb 2012 B2
8114064 Alferness et al. Feb 2012 B2
8114066 Naef et al. Feb 2012 B2
8118781 Knopper et al. Feb 2012 B2
8121603 Zhi Feb 2012 B2
D657462 Siroky Apr 2012 S
8147446 Yodat et al. Apr 2012 B2
8151169 Bieth et al. Apr 2012 B2
8152764 Istoc et al. Apr 2012 B2
8152770 Reid Apr 2012 B2
8152779 Cabiri Apr 2012 B2
8152793 Keinaenen et al. Apr 2012 B2
8157693 Waksmundzki Apr 2012 B2
8157769 Cabiri Apr 2012 B2
8162674 Cho et al. Apr 2012 B2
8162923 Adams et al. Apr 2012 B2
8167841 Feisen-Simony et al. May 2012 B2
8172591 Wertz May 2012 B2
8172804 Bikovsky May 2012 B2
8177749 Slate et al. May 2012 B2
8182447 Moberg et al. May 2012 B2
8182462 Istoc et al. May 2012 B2
8197444 Bazargan et al. Jun 2012 B1
8206351 Sugimoto et al. Jun 2012 B2
8221356 Enggaard et al. Jul 2012 B2
8257345 Adair et al. Sep 2012 B2
8267893 Moberg et al. Sep 2012 B2
8267921 Yodfat et al. Sep 2012 B2
8273061 McConnell et al. Sep 2012 B2
8287520 Drew et al. Oct 2012 B2
8292647 Mcgrath et al. Oct 2012 B1
8303572 Adair et al. Nov 2012 B2
8308679 Hanson et al. Nov 2012 B2
8308695 Laiosa Nov 2012 B2
8323250 Chong et al. Dec 2012 B2
8348898 Cabiri Jan 2013 B2
8366668 Maritan Feb 2013 B2
8372039 Mernoe et al. Feb 2013 B2
8373421 Lindegger et al. Feb 2013 B2
8409141 Johansen et al. Apr 2013 B2
8409142 Causey et al. Apr 2013 B2
8409143 Lanigan et al. Apr 2013 B2
8409149 Hommann et al. Apr 2013 B2
8414533 Alexandersson Apr 2013 B2
8414557 Istoc et al. Apr 2013 B2
8425468 Weston Apr 2013 B2
8430847 Mernoe et al. Apr 2013 B2
8465455 Cabiri Jun 2013 B2
8469942 Kow et al. Jun 2013 B2
8474332 Bente et al. Jul 2013 B2
8475408 Mernoe et al. Jul 2013 B2
8479595 Vazquez et al. Jul 2013 B2
8483980 Moberg et al. Jul 2013 B2
8490790 Cocheteux et al. Jul 2013 B2
8495918 Bazargan et al. Jul 2013 B2
8496862 Zelkovich et al. Jul 2013 B2
8500716 Adair et al. Aug 2013 B2
8512287 Cindrich et al. Aug 2013 B2
8512295 Evans et al. Aug 2013 B2
8517987 Istoc et al. Aug 2013 B2
8517992 Jones Aug 2013 B2
8523803 Favreau Sep 2013 B1
8551046 Causey et al. Oct 2013 B2
8556856 Bazargan et al. Oct 2013 B2
8562364 Lin et al. Oct 2013 B2
8568361 Yodfat et al. Oct 2013 B2
8574216 Istoc et al. Nov 2013 B2
8603026 Favreau Dec 2013 B2
8603027 Favreau Dec 2013 B2
8603028 Mudd et al. Dec 2013 B2
8617110 Moberg et al. Dec 2013 B2
8622966 Causey et al. Jan 2014 B2
8628510 Bazargan et al. Jan 2014 B2
8632499 Grant et al. Jan 2014 B2
8647074 Moberg et al. Feb 2014 B2
8647296 Moberg et al. Feb 2014 B2
8647303 Cowe Feb 2014 B2
8668672 Moberg et al. Mar 2014 B2
8674288 Hanson et al. Mar 2014 B2
8679060 Mernoe et al. Mar 2014 B2
8681010 Moberg et al. Mar 2014 B2
D702834 Norton et al. Apr 2014 S
8690855 Alderete et al. Apr 2014 B2
8708961 Field et al. Apr 2014 B2
8715237 Moberg et al. May 2014 B2
8721603 Lundquist May 2014 B2
8751237 Kubota Jun 2014 B2
8753326 Chong et al. Jun 2014 B2
8753331 Murphy Jun 2014 B2
8764707 Moberg et al. Jul 2014 B2
8764723 Chong et al. Jul 2014 B2
8771222 Kanderian et al. Jul 2014 B2
8777896 Starkweather et al. Jul 2014 B2
8777924 Kanderian et al. Jul 2014 B2
8777925 Patton Jul 2014 B2
8784369 Starkweather et al. Jul 2014 B2
8784370 Lebel et al. Jul 2014 B2
8784378 Weinandy Jul 2014 B2
8790295 Sigg et al. Jul 2014 B1
8795224 Starkweather et al. Aug 2014 B2
8795231 Chong et al. Aug 2014 B2
8795260 Drew Aug 2014 B2
8801668 Ali et al. Aug 2014 B2
8801679 Iio et al. Aug 2014 B2
8810394 Kalpin Aug 2014 B2
8814379 Griffiths et al. Aug 2014 B2
8845587 Lanigan et al. Sep 2014 B2
8858508 Lavi et al. Oct 2014 B2
8864739 Moberg et al. Oct 2014 B2
8876770 Kraft et al. Nov 2014 B2
8876778 Carrel Nov 2014 B2
8911410 Ekman et al. Dec 2014 B2
8915882 Cabiri Dec 2014 B2
8915886 Cowe Dec 2014 B2
8920374 Bokelman et al. Dec 2014 B2
8932266 Wozencroft Jan 2015 B2
8979802 Woehr Mar 2015 B2
8986250 Beebe et al. Mar 2015 B2
9011164 Filman et al. Apr 2015 B2
9011371 Moberg et al. Apr 2015 B2
9011387 Ekman et al. Apr 2015 B2
9033925 Moberg et al. May 2015 B2
9061104 Daniel Jun 2015 B2
9061110 Avery et al. Jun 2015 B2
9072827 Cabiri Jul 2015 B2
9072845 Hiles Jul 2015 B2
9089475 Fangrow Jul 2015 B2
9089641 Kavazov Jul 2015 B2
9107999 Moberg et al. Aug 2015 B2
9138534 Yodat et al. Sep 2015 B2
9149575 Cabiri Oct 2015 B2
9173996 Gray et al. Nov 2015 B2
9173997 Gross et al. Nov 2015 B2
9180248 Moberg et al. Nov 2015 B2
9205188 Lanigan et al. Dec 2015 B2
9205199 Kemp et al. Dec 2015 B2
D747799 Norton et al. Jan 2016 S
9233215 Hourmand et al. Jan 2016 B2
9259532 Cabiri Feb 2016 B2
9283327 Hourmand et al. Mar 2016 B2
9308318 Lanigan et al. Apr 2016 B2
9308327 Marshall et al. Apr 2016 B2
9314569 Causey et al. Apr 2016 B2
9320849 Smith et al. Apr 2016 B2
9327073 Moberg et al. May 2016 B2
9339607 Langley et al. May 2016 B2
9345834 Henley et al. May 2016 B2
9345836 Cabiri et al. May 2016 B2
9350634 Fadell May 2016 B2
9352090 Brereton et al. May 2016 B2
9364606 Cindrich et al. Jun 2016 B2
9364608 Moberg et al. Jun 2016 B2
9381300 Smith et al. Jul 2016 B2
9393365 Cabiri Jul 2016 B2
9421323 Cabiri et al. Aug 2016 B2
9421337 Kemp et al. Aug 2016 B2
9427531 Hourmand et al. Aug 2016 B2
9433732 Moberg et al. Sep 2016 B2
9433733 Moberg et al. Sep 2016 B2
9446188 Grant et al. Sep 2016 B2
9446196 Hourmand et al. Sep 2016 B2
9452261 Alon Sep 2016 B2
9463280 Cabiri Oct 2016 B2
9463889 Schmitz et al. Oct 2016 B2
9468720 Mudd et al. Oct 2016 B2
9474859 Ekman et al. Oct 2016 B2
9492622 Brereton et al. Nov 2016 B2
9522234 Cabiri Dec 2016 B2
9539384 Servansky Jan 2017 B2
9539388 Causey et al. Jan 2017 B2
9539757 Ramirez et al. Jan 2017 B2
9572926 Cabiri Feb 2017 B2
9572927 Bruggemann et al. Feb 2017 B2
9579452 Adair et al. Feb 2017 B2
9579471 Carrel et al. Feb 2017 B2
9610407 Bruggemann et al. Apr 2017 B2
9656019 Cabiri et al. May 2017 B2
9656021 Brereton et al. May 2017 B2
9656025 Bostrom et al. May 2017 B2
9707356 Hourmand et al. Jul 2017 B2
9744306 Cowe Aug 2017 B2
9775948 Bechmann et al. Oct 2017 B2
9782545 Gross et al. Oct 2017 B2
9789247 Kamen et al. Oct 2017 B2
9814830 Mernoe et al. Nov 2017 B2
9814839 Eaton Nov 2017 B2
9849242 Henley et al. Dec 2017 B2
9862519 Deutschle et al. Jan 2018 B2
9999722 Yodfat et al. Jun 2018 B2
10010681 Koch et al. Jul 2018 B2
10076356 Hadvary et al. Sep 2018 B2
10143794 Lanigan et al. Dec 2018 B2
10149943 Bar-El et al. Dec 2018 B2
D838367 Norton et al. Jan 2019 S
10166335 Reber et al. Jan 2019 B2
10207048 Gray et al. Feb 2019 B2
10207051 Cereda et al. Feb 2019 B2
10227161 Auerbach Mar 2019 B2
10232116 Ekman et al. Mar 2019 B2
10258740 McLoughlin et al. Apr 2019 B2
10369289 Cabiri Aug 2019 B2
10376641 Hirschel et al. Aug 2019 B2
10376647 Farris et al. Aug 2019 B2
10434262 Bendek et al. Oct 2019 B2
10500352 Grant et al. Dec 2019 B2
10561798 Holland et al. Feb 2020 B2
10576213 Gylleby Mar 2020 B2
10576220 Armes Mar 2020 B2
10583260 Kemp Mar 2020 B2
10603430 Shor et al. Mar 2020 B2
10722645 Kamen et al. Jul 2020 B2
10729847 Gray et al. Aug 2020 B2
10758679 Bar-El et al. Sep 2020 B2
10842942 Iibuchi et al. Nov 2020 B2
11027059 Niklaus et al. Jun 2021 B2
20010005781 Bergens et al. Jun 2001 A1
20010018937 Nemoto Sep 2001 A1
20010025168 Gross et al. Sep 2001 A1
20010034502 Moberg et al. Oct 2001 A1
20010041869 Causey et al. Nov 2001 A1
20020010423 Gross et al. Jan 2002 A1
20020016569 Critchlow et al. Feb 2002 A1
20020029018 Jeffrey Mar 2002 A1
20020040208 Flaherty et al. Apr 2002 A1
20020055711 Lavi et al. May 2002 A1
20020055718 Hunt May 2002 A1
20020065488 Suzuki et al. May 2002 A1
20020107487 Preuthun Aug 2002 A1
20020120186 Keimel Aug 2002 A1
20020123740 Flaherty et al. Sep 2002 A1
20020151855 Douglas et al. Oct 2002 A1
20020161332 Ramey Oct 2002 A1
20020169215 Meng Nov 2002 A1
20020173748 McConnell et al. Nov 2002 A1
20020173769 Gray et al. Nov 2002 A1
20030009133 Ramey Jan 2003 A1
20030014018 Giambattista et al. Jan 2003 A1
20030050602 Pettis et al. Mar 2003 A1
20030069518 Daley et al. Apr 2003 A1
20030125671 Aramata et al. Jul 2003 A1
20030130618 Gray et al. Jul 2003 A1
20030135159 Daily et al. Jul 2003 A1
20030160683 Blomquist Aug 2003 A1
20030167039 Moberg Sep 2003 A1
20030171717 Farrugia et al. Sep 2003 A1
20030199825 Flaherty et al. Oct 2003 A1
20030216683 Shekalim Nov 2003 A1
20030236498 Gross et al. Dec 2003 A1
20040000818 Preuthun et al. Jan 2004 A1
20040003493 Adair et al. Jan 2004 A1
20040010207 Flaherty et al. Jan 2004 A1
20040049160 Hsieh et al. Mar 2004 A1
20040049161 Sheam Mar 2004 A1
20040082911 Tiu et al. Apr 2004 A1
20040092873 Moberg May 2004 A1
20040116866 Gorman et al. Jun 2004 A1
20040122359 Wenz et al. Jun 2004 A1
20040122369 Schriver et al. Jun 2004 A1
20040127857 Shemesh et al. Jul 2004 A1
20040135078 Mandro et al. Jul 2004 A1
20040158172 Hancock Aug 2004 A1
20040158205 Savage Aug 2004 A1
20040186419 Cho Sep 2004 A1
20040186441 Graf et al. Sep 2004 A1
20040210196 Bush et al. Oct 2004 A1
20040260233 Garibotto et al. Dec 2004 A1
20050027255 Lavi et al. Feb 2005 A1
20050033234 Sadowski et al. Feb 2005 A1
20050038391 Wittland et al. Feb 2005 A1
20050065466 Vedrine Mar 2005 A1
20050065472 Cindrich et al. Mar 2005 A1
20050071487 Lu et al. Mar 2005 A1
20050113761 Faust et al. May 2005 A1
20050124940 Martin et al. Jun 2005 A1
20050154353 Alheidt Jul 2005 A1
20050159706 Wilkinson et al. Jul 2005 A1
20050171476 Judson et al. Aug 2005 A1
20050171512 Flaherty Aug 2005 A1
20050177136 Miller Aug 2005 A1
20050197626 Moberg et al. Sep 2005 A1
20050197650 Sugimoto et al. Sep 2005 A1
20050203461 Flaherty et al. Sep 2005 A1
20050238507 Diianni et al. Oct 2005 A1
20050245956 Steinemann et al. Nov 2005 A1
20050283114 Bresina et al. Dec 2005 A1
20060013716 Nason et al. Jan 2006 A1
20060030816 Zubry Feb 2006 A1
20060036216 Rimlinger et al. Feb 2006 A1
20060095010 Westbye May 2006 A1
20060095014 Ethelfeld May 2006 A1
20060122577 Poulsen et al. Jun 2006 A1
20060124269 Miyazaki et al. Jun 2006 A1
20060173406 Hayes et al. Aug 2006 A1
20060173439 Thorne et al. Aug 2006 A1
20060184154 Moberg et al. Aug 2006 A1
20060195029 Shults et al. Aug 2006 A1
20060206054 Shekalim Sep 2006 A1
20060206057 Deruntz et al. Sep 2006 A1
20060211982 Prestrelski et al. Sep 2006 A1
20060229569 Lavi et al. Oct 2006 A1
20060264888 Moberg et al. Nov 2006 A1
20060264889 Moberg et al. Nov 2006 A1
20060264890 Moberg et al. Nov 2006 A1
20060264894 Moberg et al. Nov 2006 A1
20060270987 Peter Nov 2006 A1
20060283465 Nickel et al. Dec 2006 A1
20060293722 Slatkine et al. Dec 2006 A1
20070021733 Hansen et al. Jan 2007 A1
20070025879 Vandergaw Feb 2007 A1
20070049865 Radmer et al. Mar 2007 A1
20070073228 Mernoe et al. Mar 2007 A1
20070079894 Kraus et al. Apr 2007 A1
20070118405 Campbell et al. May 2007 A1
20070167912 Causey et al. Jul 2007 A1
20070179444 Causey et al. Aug 2007 A1
20070185449 Mernoe Aug 2007 A1
20070197954 Keenan Aug 2007 A1
20070197968 Pongpairochana et al. Aug 2007 A1
20070203454 Shermer et al. Aug 2007 A1
20070233038 Pruitt et al. Oct 2007 A1
20070265568 Tsals et al. Nov 2007 A1
20070282269 Carter et al. Dec 2007 A1
20080021439 Brittingham et al. Jan 2008 A1
20080033367 Haury et al. Feb 2008 A1
20080033369 Kohlbrenner et al. Feb 2008 A1
20080033393 Edwards et al. Feb 2008 A1
20080051711 Mounce et al. Feb 2008 A1
20080051730 Bikovsky Feb 2008 A1
20080059133 Edwards et al. Mar 2008 A1
20080097326 Moberg et al. Apr 2008 A1
20080097381 Moberg et al. Apr 2008 A1
20080097387 Spector Apr 2008 A1
20080108951 Jerde et al. May 2008 A1
20080140006 Eskuri et al. Jun 2008 A1
20080140014 Miller et al. Jun 2008 A1
20080140018 Enggaard et al. Jun 2008 A1
20080147004 Mann et al. Jun 2008 A1
20080167641 Hansen et al. Jul 2008 A1
20080188813 Miller et al. Aug 2008 A1
20080208138 Lim et al. Aug 2008 A1
20080215006 Thorkild Sep 2008 A1
20080215013 Felix-Faure Sep 2008 A1
20080215015 Cindrich et al. Sep 2008 A1
20080221523 Moberg et al. Sep 2008 A1
20080243087 Enggaard et al. Oct 2008 A1
20080249473 Rutti et al. Oct 2008 A1
20080262436 Olson Oct 2008 A1
20080269687 Chong et al. Oct 2008 A1
20080269723 Mastrototaro et al. Oct 2008 A1
20080274630 Shelton et al. Nov 2008 A1
20080294143 Tanaka et al. Nov 2008 A1
20080306449 Kristensen et al. Dec 2008 A1
20080312601 Cane Dec 2008 A1
20080319383 Byland et al. Dec 2008 A1
20080319416 Yodfat et al. Dec 2008 A1
20090012478 Weston Jan 2009 A1
20090041805 Walker Feb 2009 A1
20090048347 Cohen et al. Feb 2009 A1
20090054750 Jennewine Feb 2009 A1
20090069784 Estes et al. Mar 2009 A1
20090076383 Toews et al. Mar 2009 A1
20090076453 Mejlhede et al. Mar 2009 A1
20090088694 Carter et al. Apr 2009 A1
20090088731 Campbell et al. Apr 2009 A1
20090093763 Gonnelli et al. Apr 2009 A1
20090093792 Gross et al. Apr 2009 A1
20090093793 Gross et al. Apr 2009 A1
20090105650 Wiegel et al. Apr 2009 A1
20090105663 Brand et al. Apr 2009 A1
20090124977 Jensen May 2009 A1
20090143730 De et al. Jun 2009 A1
20090143735 De et al. Jun 2009 A1
20090149830 Spector Jun 2009 A1
20090182277 Carter Jul 2009 A1
20090182284 Morgan Jul 2009 A1
20090204076 Liversidge Aug 2009 A1
20090209896 Selevan Aug 2009 A1
20090234319 Marksteiner Sep 2009 A1
20090240240 Hines et al. Sep 2009 A1
20090253973 Bashan et al. Oct 2009 A1
20090259176 Yairi Oct 2009 A1
20090281585 Katzman et al. Nov 2009 A1
20090299288 Sie et al. Dec 2009 A1
20090299290 Moberg Dec 2009 A1
20090299397 Ruan et al. Dec 2009 A1
20090326459 Shipway et al. Dec 2009 A1
20090326509 Muse et al. Dec 2009 A1
20100010455 Elahi et al. Jan 2010 A1
20100018334 Lessing Jan 2010 A1
20100030156 Beebe et al. Feb 2010 A1
20100030198 Beebe et al. Feb 2010 A1
20100049128 Mckenzie et al. Feb 2010 A1
20100049144 Mcconnell et al. Feb 2010 A1
20100057057 Hayter et al. Mar 2010 A1
20100076382 Weston Mar 2010 A1
20100076412 Rush et al. Mar 2010 A1
20100094255 Nycz et al. Apr 2010 A1
20100100076 Rush et al. Apr 2010 A1
20100100077 Rush et al. Apr 2010 A1
20100106098 Atterbury et al. Apr 2010 A1
20100121314 Iobbi May 2010 A1
20100137790 Yodfat Jun 2010 A1
20100137831 Tsais Jun 2010 A1
20100145303 Yodfat et al. Jun 2010 A1
20100145305 Alon Jun 2010 A1
20100160894 Julian et al. Jun 2010 A1
20100162548 Leidig Jul 2010 A1
20100168607 Miesel Jul 2010 A1
20100168683 Cabiri Jul 2010 A1
20100198157 Gyrn et al. Aug 2010 A1
20100204657 Yodfat et al. Aug 2010 A1
20100234767 Sarstedt Sep 2010 A1
20100234830 Straessler et al. Sep 2010 A1
20100241065 Moberg et al. Sep 2010 A1
20100241103 Kraft et al. Sep 2010 A1
20100256486 Savage Oct 2010 A1
20100264931 Lindegger et al. Oct 2010 A1
20100268169 Llewellyn-Hyde et al. Oct 2010 A1
20100274112 Hoss et al. Oct 2010 A1
20100274192 Mernoe Oct 2010 A1
20100280499 Yodfat et al. Nov 2010 A1
20100331826 Field et al. Dec 2010 A1
20110034900 Yodfat et al. Feb 2011 A1
20110054399 Chong et al. Mar 2011 A1
20110054400 Chong et al. Mar 2011 A1
20110066131 Cabiri Mar 2011 A1
20110092915 Olson et al. Apr 2011 A1
20110112504 Causey et al. May 2011 A1
20110125056 Merchant May 2011 A1
20110160654 Hanson et al. Jun 2011 A1
20110160666 Hanson et al. Jun 2011 A1
20110160669 Gyrn et al. Jun 2011 A1
20110172645 Moga et al. Jul 2011 A1
20110172745 Na et al. Jul 2011 A1
20110178463 Cabiri Jul 2011 A1
20110178472 Cabiri Jul 2011 A1
20110201998 Pongpairochana et al. Aug 2011 A1
20110224616 Slate et al. Sep 2011 A1
20110224646 Yodfat et al. Sep 2011 A1
20110238031 Mair et al. Sep 2011 A1
20110245773 Estes et al. Oct 2011 A1
20110270160 Mernoe Nov 2011 A1
20110282282 Lorenzen et al. Nov 2011 A1
20110282296 Harms et al. Nov 2011 A1
20110295205 Kaufmann et al. Dec 2011 A1
20110313238 Reichenbach et al. Dec 2011 A1
20110319861 Wilk Dec 2011 A1
20110319919 Curry et al. Dec 2011 A1
20120004602 Hanson et al. Jan 2012 A1
20120010594 Holt et al. Jan 2012 A1
20120022344 Kube Jan 2012 A1
20120022496 Causey et al. Jan 2012 A1
20120022499 Anderson et al. Jan 2012 A1
20120029431 Hwang et al. Feb 2012 A1
20120035546 Cabiri Feb 2012 A1
20120041364 Smith Feb 2012 A1
20120041387 Bruggemann et al. Feb 2012 A1
20120041414 Estes et al. Feb 2012 A1
20120071828 Tojo et al. Mar 2012 A1
20120096953 Bente et al. Apr 2012 A1
20120096954 Vazquez et al. Apr 2012 A1
20120101436 Bazargan et al. Apr 2012 A1
20120108933 Liang et al. May 2012 A1
20120109059 Ranalletta et al. May 2012 A1
20120118777 Kakiuchi et al. May 2012 A1
20120123387 Gonzalez May 2012 A1
20120129362 Hampo et al. May 2012 A1
20120160033 Kow et al. Jun 2012 A1
20120165733 Bazargan et al. Jun 2012 A1
20120165780 Bazargan et al. Jun 2012 A1
20120172817 Brüggemann et al. Jul 2012 A1
20120184917 Bom et al. Jul 2012 A1
20120226234 Bazargan et al. Sep 2012 A1
20120238961 Julian et al. Sep 2012 A1
20120259282 Alderete et al. Oct 2012 A1
20130012875 Gross et al. Jan 2013 A1
20130068319 Plumptre et al. Mar 2013 A1
20130085457 Schiff et al. Apr 2013 A1
20130089992 Yang Apr 2013 A1
20130096509 Avery et al. Apr 2013 A1
20130110049 Cronenberg et al. May 2013 A1
20130131589 Mudd et al. May 2013 A1
20130131604 Avery May 2013 A1
20130133438 Kow et al. May 2013 A1
20130172808 Gilbert Jul 2013 A1
20130190693 Ekman et al. Jul 2013 A1
20130200549 Felts et al. Aug 2013 A1
20130204187 Avery et al. Aug 2013 A1
20130204191 Cindrich et al. Aug 2013 A1
20130237953 Kow et al. Sep 2013 A1
20130245595 Kow et al. Sep 2013 A1
20130245596 Cabiri et al. Sep 2013 A1
20130245604 Kouyoumjian et al. Sep 2013 A1
20130253419 Favreau Sep 2013 A1
20130253420 Favreau Sep 2013 A1
20130253421 Favreau Sep 2013 A1
20130253434 Cabiri Sep 2013 A1
20130267895 Hemmingsen Oct 2013 A1
20130296799 Degtiar et al. Nov 2013 A1
20130296824 Mo et al. Nov 2013 A1
20130304021 Cabiri et al. Nov 2013 A1
20130310753 Cabiri Nov 2013 A1
20130310807 Adair et al. Nov 2013 A1
20130323699 Edwards et al. Dec 2013 A1
20130331791 Gross et al. Dec 2013 A1
20130338584 Mounce et al. Dec 2013 A1
20140018735 Causey et al. Jan 2014 A1
20140031747 Ardehali Jan 2014 A1
20140055073 Favreau Feb 2014 A1
20140055076 Favreau Feb 2014 A1
20140058349 Bazargan et al. Feb 2014 A1
20140083517 Moia et al. Mar 2014 A1
20140094755 Bazargan et al. Apr 2014 A1
20140121633 Causey et al. May 2014 A1
20140128807 Moberg et al. May 2014 A1
20140128835 Moberg et al. May 2014 A1
20140135692 Alderete et al. May 2014 A1
20140135694 Moberg et al. May 2014 A1
20140142499 Moberg et al. May 2014 A1
20140148784 Anderson et al. May 2014 A1
20140148785 Moberg et al. May 2014 A1
20140163522 Alderete et al. Jun 2014 A1
20140163526 Cabiri et al. Jun 2014 A1
20140171881 Cabiri Jun 2014 A1
20140174223 Gross et al. Jun 2014 A1
20140194819 Maule et al. Jul 2014 A1
20140194854 Tsals Jul 2014 A1
20140207064 Yavorsky Jul 2014 A1
20140207065 Yavorsky Jul 2014 A1
20140207066 Yavorsky Jul 2014 A1
20140207104 Vouillamoz et al. Jul 2014 A1
20140213975 Clemente et al. Jul 2014 A1
20140214001 Mortazavi Jul 2014 A1
20140228768 Eggert et al. Aug 2014 A1
20140236087 Alderete et al. Aug 2014 A1
20140243786 Gilbert et al. Aug 2014 A1
20140261758 Wlodarczyk et al. Sep 2014 A1
20140343503 Holmqvist Nov 2014 A1
20140364808 Niklaus et al. Dec 2014 A1
20150005703 Hutchinson et al. Jan 2015 A1
20150073344 Van Damme et al. Mar 2015 A1
20150088071 Cabiri Mar 2015 A1
20150112278 Ray et al. Apr 2015 A1
20150119798 Gross et al. Apr 2015 A1
20150157806 Knutsson Jun 2015 A1
20150202375 Schabbach et al. Jul 2015 A1
20150374926 Gross et al. Dec 2015 A1
20160030665 Cabiri Feb 2016 A1
20160051756 Cabiri Feb 2016 A1
20160144117 Chun May 2016 A1
20160151586 Kemp Jun 2016 A1
20160175515 Mccullough Jun 2016 A1
20160184512 Marbet et al. Jun 2016 A1
20160193406 Cabiri Jul 2016 A1
20160199590 Schabbach et al. Jul 2016 A1
20160213840 Schabbach et al. Jul 2016 A1
20160220755 Lanigan et al. Aug 2016 A1
20160228652 Cabiri et al. Aug 2016 A1
20160296713 Schader et al. Oct 2016 A1
20160296716 Cabiri et al. Oct 2016 A1
20160331900 Wei Nov 2016 A1
20160339168 Hutchinson et al. Nov 2016 A1
20160346478 Bar-El et al. Dec 2016 A1
20160354553 Anderson Dec 2016 A1
20170007774 Brockmeier Jan 2017 A1
20170043092 Murakami et al. Feb 2017 A1
20170058349 Levy et al. Mar 2017 A1
20170175859 Brockmeier Jun 2017 A1
20170246399 Forlani et al. Aug 2017 A1
20170246403 Cowe et al. Aug 2017 A1
20180028765 Waller et al. Feb 2018 A1
20180133413 Grant et al. May 2018 A1
20180214637 Kemp et al. Aug 2018 A1
20180304029 Koch et al. Oct 2018 A1
20190022306 Gibson et al. Jan 2019 A1
20190060578 Farris et al. Feb 2019 A1
20190071217 Brown et al. Mar 2019 A1
20190099549 Lanigan et al. Apr 2019 A1
20190175821 Kamen et al. Jun 2019 A1
20190224415 Dugand et al. Jul 2019 A1
20190240417 Hostettler et al. Aug 2019 A1
20190328968 Giambattista Oct 2019 A1
20200009323 Nair et al. Jan 2020 A1
20200164151 Farris et al. May 2020 A1
20200215270 Ogawa et al. Jul 2020 A1
20200297929 Zhang Sep 2020 A1
20200360602 Gray et al. Nov 2020 A1
20210138157 Bar-El et al. May 2021 A1
20210220551 Dowd et al. Jul 2021 A1
Foreign Referenced Citations (218)
Number Date Country
1505535 Jun 2004 CN
1747683 Mar 2006 CN
1863566 Nov 2006 CN
101090749 Dec 2007 CN
101227943 Jul 2008 CN
101448536 Jun 2009 CN
101522235 Sep 2009 CN
101541362 Sep 2009 CN
101641126 Feb 2010 CN
201692438 Jan 2011 CN
201941304 Aug 2011 CN
102186733 Sep 2011 CN
102378638 Mar 2012 CN
105102025 Nov 2015 CN
0855313 Nov 1952 DE
1064693 Sep 1959 DE
19518807 Dec 1995 DE
19717107 Nov 1998 DE
0017412 Oct 1980 EP
0222656 May 1987 EP
0401179 Dec 1990 EP
0851774 Jul 1998 EP
0925082 Jun 1999 EP
1003581 May 2000 EP
1124600 Aug 2001 EP
1219312 Jul 2002 EP
1472477 Nov 2004 EP
1530979 May 2005 EP
1666080 Jun 2006 EP
1372762 Feb 2007 EP
1974759 Oct 2008 EP
2060606 May 2009 EP
2140897 Jan 2010 EP
2173413 Apr 2010 EP
2185227 May 2010 EP
2192935 Jun 2010 EP
2361648 Aug 2011 EP
2364739 Sep 2011 EP
2393534 Dec 2011 EP
2452708 May 2012 EP
2498589 Sep 2012 EP
2574355 Apr 2013 EP
2393535 Mar 2015 EP
2878321 Jun 2015 EP
2886144 Jun 2015 EP
1904130 Mar 2016 EP
2991705 Mar 2016 EP
3266478 Jan 2018 EP
2819724 Mar 2019 EP
2770136 Apr 1999 FR
2436526 Oct 2007 GB
62-112566 May 1987 JP
01-172843 Dec 1989 JP
05-062828 Mar 1993 JP
07-194701 Aug 1995 JP
3035448 Mar 1997 JP
09-505758 Jun 1997 JP
11-507260 Jun 1999 JP
2000-107289 Apr 2000 JP
2000-515394 Nov 2000 JP
2001-512992 Aug 2001 JP
2002-505601 Feb 2002 JP
2002-507459 Mar 2002 JP
2002-528676 Sep 2002 JP
2003-501157 Jan 2003 JP
2003-534061 Nov 2003 JP
2004-501721 Jan 2004 JP
2004-512100 Apr 2004 JP
2003-527138 Aug 2005 JP
2005-523127 Aug 2005 JP
2005-527249 Sep 2005 JP
2005-270629 Oct 2005 JP
2006-507067 Mar 2006 JP
2006-510450 Mar 2006 JP
2006-525046 Nov 2006 JP
2007-509661 Apr 2007 JP
2007-306990 Nov 2007 JP
2008-534131 Aug 2008 JP
2008-220961 Sep 2008 JP
2009-502273 Jan 2009 JP
2009-101093 May 2009 JP
2010-501281 Jan 2010 JP
2010-540054 Dec 2010 JP
2010-540156 Dec 2010 JP
2011-136153 Jul 2011 JP
2012-100927 May 2012 JP
4947871 Jun 2012 JP
2013-500811 Jan 2013 JP
2013-505433 Feb 2013 JP
2013-517095 May 2013 JP
2013-519473 May 2013 JP
2013-530778 Aug 2013 JP
2013-531520 Aug 2013 JP
2013-531540 Aug 2013 JP
2014-030489 Feb 2014 JP
2014-515669 Jul 2014 JP
2014-518743 Aug 2014 JP
2014-521443 Aug 2014 JP
2014-525339 Sep 2014 JP
2015-514486 May 2015 JP
2016-525428 Aug 2016 JP
2016-530016 Sep 2016 JP
9009202 Aug 1990 WO
9307922 Apr 1993 WO
9407553 Apr 1994 WO
9415660 Jul 1994 WO
9513838 May 1995 WO
9609083 Mar 1996 WO
9632975 Oct 1996 WO
9700091 Jan 1997 WO
9710012 Mar 1997 WO
9721457 Jun 1997 WO
9733638 Sep 1997 WO
9857683 Dec 1998 WO
9857686 Dec 1998 WO
9929151 Jun 1999 WO
9938554 Aug 1999 WO
9959665 Nov 1999 WO
0025844 May 2000 WO
0069509 Nov 2000 WO
0130415 May 2001 WO
0130421 May 2001 WO
0170304 Sep 2001 WO
0172357 Oct 2001 WO
0187384 Nov 2001 WO
0189607 Nov 2001 WO
0189613 Nov 2001 WO
0202165 Jan 2002 WO
0204049 Jan 2002 WO
0234315 May 2002 WO
0238204 May 2002 WO
0256934 Jul 2002 WO
0256943 Jul 2002 WO
0272182 Sep 2002 WO
0362672 Jul 2003 WO
0390833 Nov 2003 WO
2004000397 Dec 2003 WO
2004032990 Apr 2004 WO
2004098684 Nov 2004 WO
2004105841 Dec 2004 WO
2005018703 Mar 2005 WO
2005037350 Apr 2005 WO
2005070485 Aug 2005 WO
2005072795 Aug 2005 WO
2006018617 Feb 2006 WO
2006037434 Apr 2006 WO
2006052737 May 2006 WO
2006069380 Jun 2006 WO
2006102676 Sep 2006 WO
2006104806 Oct 2006 WO
2006121921 Nov 2006 WO
2007017052 Feb 2007 WO
2007051563 May 2007 WO
2007056504 May 2007 WO
2007066152 Jun 2007 WO
2007073228 Jun 2007 WO
2007119178 Oct 2007 WO
2008001377 Jan 2008 WO
2008014908 Feb 2008 WO
2008057976 May 2008 WO
2008072229 Jun 2008 WO
2008076459 Jun 2008 WO
2008078318 Jul 2008 WO
2009019438 Feb 2009 WO
2009022132 Feb 2009 WO
2009043000 Apr 2009 WO
2009043564 Apr 2009 WO
2009044401 Apr 2009 WO
2009046989 Apr 2009 WO
2009069064 Jun 2009 WO
2009125398 Oct 2009 WO
2009144085 Dec 2009 WO
2010078227 Jul 2010 WO
2010078242 Jul 2010 WO
2010089313 Aug 2010 WO
2011075105 Jun 2011 WO
2011090955 Jul 2011 WO
2011090956 Jul 2011 WO
2011101378 Aug 2011 WO
2011110872 Sep 2011 WO
2011124631 Oct 2011 WO
2011129175 Oct 2011 WO
2011131778 Oct 2011 WO
2011131780 Oct 2011 WO
2011131781 Oct 2011 WO
2011133823 Oct 2011 WO
2011156373 Dec 2011 WO
2012003221 Jan 2012 WO
2012032411 Mar 2012 WO
2012040528 Mar 2012 WO
2012145752 Oct 2012 WO
2012160157 Nov 2012 WO
2012168691 Dec 2012 WO
2013036602 Mar 2013 WO
2013058697 Apr 2013 WO
2013115843 Aug 2013 WO
2014132293 Sep 2014 WO
2014179117 Nov 2014 WO
2014179774 Nov 2014 WO
2014194183 Dec 2014 WO
2015048791 Apr 2015 WO
2015048803 Apr 2015 WO
2015078868 Jun 2015 WO
2015091758 Jun 2015 WO
2015091850 Jun 2015 WO
2015114158 Aug 2015 WO
2015114428 Aug 2015 WO
2015118358 Aug 2015 WO
2015163009 Oct 2015 WO
2016087626 Jun 2016 WO
2016087627 Jun 2016 WO
2016141082 Sep 2016 WO
2017022639 Feb 2017 WO
2017161076 Sep 2017 WO
2018222521 Dec 2018 WO
2019224782 Nov 2019 WO
2020120087 Jun 2020 WO
2020193468 Oct 2020 WO
Non-Patent Literature Citations (183)
Entry
US 8,333,733 B2, 12/2012, Lanigan et al. (withdrawn)
Communication Pursuant to Rules 161 and 162 dated Apr. 6, 2018 in EP Application No. 16784688.0.
Copaxone(Registered), Innovative Drugs, Teva Pharmaceuticals, downloaded from webpage http://levapharm.com/copaxone/, Download date: Jan. 2009, original posting date: unknown, 3 pages.
Daikyo Crystal Zenith(Registered) polymer, Manufactured by Daikyo Seiko, Lid. (Jun. 25, 2008).
Definition of Monolithic. In Merriam-Webster's online dictionary. Retrieved from https://www.merriam-webster.com/dictionary/monolithic (Year 2021).
English translation of an Office Action dated Jan. 30, 2013 in CN Application No. 200880117084.X.
English translation of an Office Action dated Mar. 5, 2014 in CN Application No. 200880117084.X.
European Search Report (Partial) dated Mar. 8, 2017 in EP Application 16193157.1.
Extended European Search Report dated Aug. 7, 2014 in EP Application No. 14174774.
Extended European Search Report dated Feb. 12, 2018 in EP Application No. 17191756.0.
Extended European Search Report dated Feb. 13, 2017 in EP Application No. 16171626.1.
Extended European Search Report dated Feb. 23, 2015 in EP Application No. 14166591.9.
Extended European Search Report dated Feb. 23, 2015 in EP Application No. 14166596.8.
Extended European Search Report dated Jul. 3, 2017 in EP Application No. 16190054.3.
Extended European Search Report dated Mar. 27, 2014 in EP Application No. 14154717.4.
Extended European Search Report dated Mar. 8, 2016 in EP Application No. 14166592.7.
Extended European Search Report dated Nov. 10, 2016 in EP Application No. 08808111.2.
Extended European Search Report dated Jul. 28, 2020 in European Application No. 20172466.3.
Extended Search Report dated Aug. 7, 2014 in EP Application No. 14171477.4.
Extended Search Report dated Jul. 7, 2017 in EP Application No. 16193157.1.
Int'l Preliminary Report on Patentability dated Nov. 22, 2017 in Int'l Application No. PCT/US2016/068371.
Int'l Search Report and Written Opinion dated Jan. 12, 2011 in Int'l Application No. PCT/US2010/048556; Written Opinion.
Int'l Search Report and Written Opinion dated Jan. 26, 2017 in Int'l Application No. PCT/US2016/056213.
Int'l Search Report and Written Opinion dated Mar. 27, 2017 in Int'l Application No. PCT/US2016/056247.
Int'l Search Report and Written Opinion dated Apr. 21, 2017 in Int'l Application No. PCT/US2016/068367.
Int'l Search Report and Written Opinion dated May 15, 2017 in Int'l Application No. PCT/US2016/068371.
Int'l Search Report and Written Opinion dated Jul. 6, 2017 in Int'l Application No. PCT/US2017/022966.
Int'l Search Report and Written Opinion dated Nov. 28, 2016 in Int'l Application No. PCT/US2016/056218.
Int'l Search Report and Written Opinion dated Dec. 2, 2016 in Int'l Application No. PCT/US2016/056210.
Int'l Search Report and Written Opinion dated Dec. 5, 2016 in Int'l Application No. PCT/US2016/056233.
Int'l Search Report and Written Opinion dated Dec. 8, 2016 in Inl'l Application No. PCT/US2016/056227.
Int'l Search Report and Written Opinion dated Dec. 15, 2016 in Inl'l Application No. PCT/US2016/056258.
Int'l Search Repport (Partial), dated Dec. 20, 2016 in Int'l Application No. PCT/US2016/056247.
Int'l Preliminary Report on Patentability dated Jan. 8, 2018 in Int'l Application No. PCT/US2016/056218.
Int'l Preliminary Report on Patentability dated Apr. 7, 2010 in Int'l Application No. PCT/IL2008/001312.
Int'l Preliminary Report on Patentability dated Aug. 2, 2012 in Int'l Application No. PCT/US2011/021604.
Int'l Preliminary Report on Patentability dated Feb. 7, 2013 in Int'l Application No. PCT/US11/21605.
Int'l Preliminary Report on Patentability dated Jan. 18, 2018 in Int'l Application No. PCT/US2016/056210.
Int'l Preliminary Report on Patentability dated Jan. 18, 2018 in Int'l Application No. PCT/US2016/056213.
Int'l Preliminary Report on Patentability dated Jan. 18, 2018 in Int'l Application No. PCT/US2016/056223.
Int'l Preliminary Report on Patentability dated Jan. 18, 2018 in Int'l Application No. PCT/US2016/056227.
Int'l Preliminary Report on Patentability dated Jul. 16, 2015 in Int'l Application No. PCT/US2013/078040.
Int'l Preliminary Report on Patentability dated May 14, 2015 in Int'l Application No. PCT/US2013/065211.
Int'l Preliminary Report on Patentability dated Nov. 27, 2014 in Int'l Application No. PCT/US2013/039465.
Int'l Preliminary Report on Patentability dated Nov. 30, 2017 in Int'l Application No. PCT/US2016/068367.
Int'l Preliminary Report on Patentability dated Nov. 9, 2018 in Int'l Application No. PCT/US2016/056238.
Int'l Preliminary Report on Patentability dated Oct. 9, 2014 in Int'l Application No. PCT/US2013/033118.
Int'l Preliminary Report on Patentability dated Sep. 1, 2011 in Int'l Application No. PCT/US2010/048556.
Int'l Search Report and Written Opinion dated Apr. 3, 2014 in Int'l Application No. PCT/US2013/078040.
Int'l Search Report and Written Opinion dated Aug. 5, 2013 in Int'l Application No. PCT/US2013/033118.
Int'l Search Report and Written Opinion dated Jan. 7, 2014 in Int'l Application No. PCT/US2013/065211.
Int'l Search Report and Written Opinion dated Jul. 12, 2017 in Int'l Application No. PCT/US2016/056238.
Int'l Search Report and Written Opinion dated Jul. 26, 2013 in Int'l Application No. PCT/US2012/039465.
Int'l Search Report and Written Opinion dated Jul. 31, 2014 in Int'l Application No. PCT/US2014/033598.
Int'l Search Report and Written Opinion dated May 13, 2009 in Int'l Application No. PCT/IL2008/001312.
Int'l Search Report dated Apr. 26, 2010 in Int'l Application No. PCT/US2009/069552.
Int'l Search Report dated Jun. 17, 2011 in Int'l Application No. PCT/US2011/021604.
Int'l Search Report dated Oct. 12, 2011 in Int'l Application No. PCT/US11/21605.
Int'l Search Report dated Sep. 22, 2011 in Int'l Application No. PCT/IL11/00368; Written Opinion.
Int'l Written Opinion dated Jul. 19, 2012 in Int'l Application No. PCT/US11/21605.
Inte'l Search Report and Written Opinion dated Nov. 30, 2016 in Int'l Application No. PCT/US2016/056223.
International Preliminary Report on Patentability and Written Opinion dated Jul. 5, 2011 in International Application No. PCT/US2009/069552.
Notice of Allowance dated Aug. 24, 2015 in U.S. Appl. No. 29/479,307 by Norton.
Offce Action dated Sep. 21, 2010 in U.S. Appl. No. 12/244,666 by Gross.
Office Action dated Apr. 22, 2016 in CN Application No. 2014102892041.
Office Action dated Apr. 5, 2010 in U.S. Appl. No. 12/244,666 by Gross.
Office Action dated Apr. 5, 2010 in U.S. Appl. No. 12/244,688 by Gross.
Office Action dated Aug. 13, 2015 in U.S. Appl. No. 14/553,399 by Cabiri.
Office Action dated Aug. 14, 2017 in CN Application No. 201410178318.9.
Office Action dated Aug. 15, 2013 in CN Application No. 200880117084.X.
Office Action dated Aug. 26, 2014 in CN Application No. 201180006567.4.
Office Action dated Aug. 6, 2014 in EP Appl. No. 11 707 942.6.
Office Action dated Dec. 1, 2015 in CN Application No. 201410289204.1.
Office Action dated Dec. 10, 2013 in CN Application No. 201180006567.4.
Office Action dated Dec. 15, 2017 in U.S. Appl. No. 15/269,248, by Cabiri.
Office Action dated Dec. 17, 2013 in JP Application No. 2012-529808.
Office Action dated Dec. 4, 2017 in CN Application No. 201410178374.2.
Office Action dated Dec. 9, 2016 in U.S. Appl. No. 14/593,051, by Gross.
Office Action dated Feb. 16, 2017 in CN Application No. 2014101783189.
Office Action dated Feb. 20, 2015 in U.S. Appl. No. 13/521,181 by Cabiri.
Office Action dated Feb. 21, 2012 in U.S. Appl. No. 12/689,249.
Office Action dated Feb. 24, 2015 in U.S. Appl. No. 14/258,661 by Cabiri.
Office Action dated Feb. 24, 2017 in U.S. Appl. No. 13/964,651, by Gross.
Office Action dated Feb. 28, 2014 in CN Application No. 201180006571.0.
Office Action dated Feb. 4, 2014 in EP Application No. 11 707 942.6.
Office Action dated Jan. 10, 2017 in U.S. Appl. No. 14/193,692, by Gross.
Office Action dated Jan. 30, 2013 in CN Application No. 200880117084.X.
Office Action dated Jan. 8, 2013 in JP Application No. 2010-527595.
Office Action dated Jan. 8, 2014 in U.S. Appl. No. 13/521,167 by Cabiri.
Office Action dated Jul. 13, 2011 in U.S. Appl. No. 12/559,563 by Cabiri.
Office Action dated Jul. 2, 2012 in U.S. Appl. No. 13/272,555 by Cabiri.
Office Action dated Jul. 28, 2020 in Japanese Application No. 2018-538074.
Office Action dated Jul. 3, 2017 in CN Application No. 2014101783742.
Office Action dated Jul. 31, 2015 in U.S. Appl. No. 13/521,181 by Cabiri.
Office Action dated Jul. 7, 2014 in U.S. Appl. No. 12/244,666 by Gross.
Office Action dated Jun. 10, 2016 in U.S. Appl. No. 13/964,651 by Gross.
Office Action dated Jun. 14, 2018 in U.S. Appl. No. 13/874,121, by Degtiar.
Office Action dated Jun. 2, 2016 in CN Application No. 2014101783189.
Office Action dated Jun. 3, 2014 in JP Application No. 2010-527595.
Office Action dated Jun. 4, 2015 in U.S. Appl. No. 13/667,739 by Cabiri.
Office Action dated Nov. 6, 2015 in U.S. Appl. No. 14/715,791 by Cabiri.
Office Action dated Oct. 6, 2020 in Japanese Application No. 2018-538527.
Partial European Search Report dated Nov. 24, 2015 in EP Application No. 14166592.7.
Search Report dated Oct. 14, 2016 in CN Application No. 2014101783742.
U.S. Appl. No. 12/559,563, filed Sep. 15, 2009.
U.S. Appl. No. 12/689,249, filed Jan. 19, 2010.
U.S. Appl. No. 12/689,250, filed Jan. 19, 2010.
U.S. Appl. No. 13/429,840 by Cabiri, filed Mar. 26, 2012.
U.S. Appl. No. 13/472,112 by Cabiri, filed May 15, 2012.
U.S. Appl. No. 13/521,167 by Cabiri, filed Jul. 9, 2012.
U.S. Appl. No. 13/521,181 by Cabiri, filed Jul. 9, 2012.
U.S. Appl. No. 13/643,470 by Alon, filed Oct. 25, 2012.
U.S. Appl. No. 13/733,516 by Cabiri, filed Jan. 3, 2013.
U.S. Appl. No. 13/873,335 by Filman, filed Apr. 30, 2013.
U.S. Appl. No. 13/874,017 by Cabiri, filed Apr. 30, 2013.
U.S. Appl. No. 13/874,085 by Cabiri, filed Apr. 30, 2013.
U.S. Appl. No. 13/874,121 by Degtiar, filed Apr. 30, 2013.
U.S. Appl. No. 13/892,905 by Cabiri, filed May 13, 2013.
U.S. Appl. No. 13/964,651 by Gross, filed Aug. 12, 2013.
U.S. Appl. No. 14/193,692 by Gross, filed Feb. 28, 2014.
U.S. Appl. No. 14/258,661 by Cabiri, filed Apr. 22, 2014.
U.S. Appl. No. 14/553,399 by Cabiri, filed Nov. 25, 2014.
U.S. Appl. No. 14/593,051 by Gross, filed Jan. 9, 2015.
U.S. Appl. No. 14/638,525 by Filman, filed Mar. 4, 2015.
U.S. Appl. No. 14/683,193 by Cabiri, filed Apr. 10, 2015.
U.S. Appl. No. 14/715,791 by Cabiri, filed May 19, 2015.
U.S. Appl. No. 14/725,009 by Bar-El, filed May 29, 2015.
U.S. Appl. No. 14/850,450 by Gross, filed Sep. 10, 2015.
U.S. Appl. No. 14/861,478 by Cabiri, filed Sep. 22, 2015.
U.S. Appl. No. 14/880,673 by Cabiri, filed Oct. 12, 2015.
U.S. Appl. No. 29/479,307 by Norton, filed Jan. 14, 2014.
U.S. Appl. No. 60/997,459, filed Oct. 2, 2007.
West Introduces the Daikyo Crystal Zenith RU Prefillable Syringe, Pharmaceutical Online, Jun. 2008, downloaded from webpage: http://www.pharmaceuticalonline.com/article.mvc/west-introduces-prefillab-le-syringe-system, Download date: Jan. 2009, original posting date: Jun. 2008, 2 pages.
Office Action dated Jun. 9, 2017 in EP Application No. 14166591.9.
Office Action dated Jun. 9, 2017 in EP Application No. 14166596.8.
Office Action dated Mar. 1, 2018 in EP Application No. 14166592.7.
Office Action dated Mar. 10, 2015 in CN Application No. 201180006567.4.
Office Action dated Mar. 10, 2015 in U.S. Appl. No. 12/244,666 by Gross.
Office Action dated Mar. 10, 2015 in U.S. Appl. No. 13/643,470 by Alon.
Office Action dated Mar. 30, 2018 in U.S. Appl. No. 14/850,450 by Gross.
Office Action dated Mar. 31, 2015 in JP Application No. 2012-550068.
Office Action dated Mar. 5, 2014 in CN Application No. 200880117084.X.
Office Action dated May 1, 2015 in U.S. Appl. No. 14/638,525 by Filman.
Office Action dated May 13, 2015 in CN Application No. 201380025566.3.
Office Action dated May 14, 2018 in EP Application No. 08808111 2.
Office Action dated May 16, 2012 in U.S. Appl. No. 12/615,828.
Office Action dated May 18, 2018 in EP 14166591.9.
Office Action dated May 23, 2014 in U.S. Appl. No. 13/472,112 by Cabiri.
Office Action dated May 24, 2017 in U.S. Appl. No. 13/874,121, by Degtiar.
Office Action dated May 25, 2021 in Japanese Office Action 2018-538073.
Office Action dated May 3, 2012 in CN Application No. 200880117084.X.
Office Action dated May 31, 2016 in U.S. Appl. No. 14/593,051 by Gross.
Office Action dated May 4, 2017 in CN Application No. 2014101836665.
Office Action dated May 5, 2015 in CN Application No. 201180006571.0.
Office Action dated May 7, 2015 in JP Application No. 2012-550069.
Office Action dated Nov. 10, 2016 in U.S. Appl. No. 13/874,121, by Degtiar.
Office Action dated Nov. 13, 2017 in U.S. Appl. No. 14/193,692, by Gross.
Office Action dated Nov. 2, 2014 in CN Application No. 201180006571.0.
Office Action dated Nov. 21, 2014 in U.S. Appl. No. 13/429,840 by Cabiri.
Office Action dated Nov. 21, 2014 in U.S. Appl. No. 13/472,112 by Cabiri.
Office Action dated Nov. 25, 2016 in U.S. Appl. No. 13/874,017, by Cabiri.
Office Action dated Nov. 4, 2013 in EP Application No. 11 709 234.6.
Office Action dated Nov. 5, 2013 in JP Application No. 2010-527595.
Office Action dated Nov. 5, 2014 in U.S. Appl. No. 13/643,470 by Alon.
Office Action dated Nov. 8, 2017 in U.S. Appl. No. 13/874,121, by Degtiar.
Office Action dated Oct. 13, 2020 in Japanese Application No. 2018-538073.
Office Action dated Oct. 2, 2018 in JP Application No. 2018-535062 (Year: 2018).
Office Action dated Oct. 28, 2011 in U.S. Appl. No. 12/615,828.
Office Action dated Oct. 28, 2016 in CN Application No. 2014101783742.
Office Action dated Oct. 5, 2016 in U.S. Appl. No. 13/964,651, by Gross.
Office Action dated Oct. 6, 2017 in U.S. Appl. No. 14/861,478, by Cabiri.
Office Action dated Oct. 9, 2014 in U.S. Appl. No. 13/873,335.
Office Action dated Sep. 18, 2015 in U.S. Appl. No. 13/874,085 by Cabiri.
Office Action dated Sep. 2, 2010 in U.S. Appl. No. 12/244,688 by Gross.
Office Action dated Sep. 2, 2014 in JP Application No. 2012-550068.
Office Action dated Sep. 2, 2014 in JP Application No. 2012-550069.
Office Action dated Sep. 28, 2017 in IN Application No. 2528/DELNP/2010.
Office Action dated Sep. 29, 2013 in CN Application No. 201080040968.7.
Office Action dated Sep. 30, 2010 in U.S. Appl. No. 12/689,250, by Cabiri.
Office Action dated Sep. 30, 2015 in U.S. Appl. No. 13/667,739 by Cabiri.
Office Action dated Sep. 6, 2011 in U.S. Appl. No. 12/345,818.
Office Action dated Sep. 9, 2015 in U.S. Appl. No. 13/643,470 by Alon.
Office Action dated Aug. 17, 2021 in Indian Application No. 201827027625.
Related Publications (1)
Number Date Country
20210361870 A1 Nov 2021 US
Provisional Applications (2)
Number Date Country
62281536 Jan 2016 US
62284806 Oct 2015 US
Divisions (1)
Number Date Country
Parent 15766437 US
Child 16448517 US
Continuations (3)
Number Date Country
Parent 16448517 Jun 2019 US
Child 17392374 US
Parent 15269248 Sep 2016 US
Child 15766437 US
Parent 15204542 Jul 2016 US
Child 15269248 US